Elevance Health (ELV) 10-Q/A 29 Sep 23 2023 Q2 Quarterly report (amended) Financial data

Document And Entity Information

Document And Entity Information Document - shares	6 Months Ended
	Jun. 30, 2023	Jul. 13, 2023
Entity Information [Line Items]
Document Type	10-Q/A
Amendment Flag	true
Amendment Description	Elevance Health, Inc. is filing this Amendment No. 1 on Form 10-Q/A (this “Amendment”) to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, which was originally filed on July 19, 2023 (“Original Filing”), solely to add inline eXtensible Business Reporting Language (“iXBRL”) data tagging that was inadvertently omitted from the disclosure included in the Original Filing under Part II, “Item 5. Other Information.”Except for the iXBRL specifically noted above, this Amendment does not modify or update any disclosures in the Original Filing. Accordingly, this Amendment does not reflect events occurring after the filing of the Original Filing or modify or update any disclosures, other than those identified above.
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0001156039
Entity File Number	001-16751
Entity Registrant Name	ELEVANCE HEALTH, INC.
Entity Incorporation, State or Country Code	IN
Entity Tax Identification Number	35-2145715
Entity Address, Address Line One	220 Virginia Avenue
Entity Address, City or Town	Indianapolis
Entity Address, State or Province	IN
Entity Address, Postal Zip Code	46204
City Area Code	833
Local Phone Number	401-1577
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	ELV
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		235,647,808

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 9,991	$ 7,387
Fixed maturities, current	28,021	25,952
Equity securities	272	953
Premium receivables	7,431	7,083
Self-funded receivables	3,896	4,663
Other receivables	5,196	4,298
Other current assets	4,936	5,281
Total current assets	59,743	55,617
Long-term investments:
Fixed maturities, long-term	775	752
Other invested assets	5,993	5,685
Property and equipment, net	4,547	4,316
Goodwill	25,274	24,383
Other intangible assets	10,703	10,315
Other noncurrent assets	2,133	1,687
Total assets	109,168	102,755
Current Liabilities:
Medical claims payable	16,165	15,596
Other policyholder liabilities	5,954	5,933
Unearned income	4,458	1,112
Accounts payable and accrued expenses	5,033	5,607
Short-term borrowings	265	265
Current portion of long-term debt	0	1,500
Other current liabilities	9,696	9,683
Total current liabilities	41,571	39,696
Long-term debt, less current portion	24,859	22,349
Reserves for future policy benefits, noncurrent	797	803
Deferred tax liabilities, net	1,852	2,015
Other noncurrent liabilities	1,777	1,562
Total liabilities	70,856	66,425
Commitments and contingencies – Note 10
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Shareholders' equity
Preferred stock, without par value, shares authorized – 100,000,000; shares issued and outstanding – none	$ 0	$ 0
Common stock, par value $0.01, shares authorized – 900,000,000; shares issued and outstanding – 235,861,650 and 237,958,067	2	2
Additional paid-in capital	8,761	9,084
Retained earnings	31,608	29,647
Accumulated other comprehensive loss	(2,166)	(2,490)
Total shareholders' equity	38,205	36,243
Noncontrolling interests	107	87
Total equity	38,312	36,330
Total liabilities and shareholders' equity	$ 109,168	$ 102,755

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Fixed maturities, amortized cost, current	$ 29,915	$ 28,226
Fixed maturities, allowance for credit loss, current	7	9
Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent	809	789
Fixed maturities, allowance for credit Loss, noncurrent	$ 0	$ 0
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	900,000,000	900,000,000
Common stock, shares issued	235,861,650	237,958,067
Common stock, shares outstanding	235,861,650	237,958,067

Consolidated Statements Of Inco

Consolidated Statements Of Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenues
Premiums	$ 36,589	$ 33,076	$ 72,457	$ 65,861
Product revenue	4,859	3,568	8,881	6,869
Service fees	1,929	1,838	3,937	3,638
Total operating revenue	43,377	38,482	85,275	76,368
Net investment income	416	381	803	741
Net losses on financial instruments	(121)	(231)	(234)	(382)
Total revenues	43,672	38,632	85,844	76,727
Expenses
Benefit expense	31,604	28,795	62,390	57,026
Cost of products sold	4,327	3,069	7,808	5,952
Operating expense	4,818	4,272	9,618	8,617
Interest expense	261	208	512	409
Amortization of other intangible assets	221	166	456	295
Total expenses	41,231	36,510	80,784	72,299
Income before income tax expense	2,441	2,122	5,060	4,428
Income tax expense	585	488	1,200	1,015
Net income	1,856	1,634	3,860	3,413
Net (income) loss attributable to noncontrolling interests	(3)	3	(18)	13
Shareholders’ net income	$ 1,853	$ 1,637	$ 3,842	$ 3,426
Shareholders’ net income per share
Basic net income per share	$ 7.83	$ 6.80	$ 16.21	$ 14.22
Diluted net income per share	7.79	6.73	16.10	14.05
Dividends per share	$ 1.48	$ 1.28	$ 2.96	$ 2.56

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Statement of Comprehensive Income [Abstract]
Net income	$ 1,856	$ 1,634	$ 3,860	$ 3,413
Other comprehensive (loss) income, net of tax:
Change in net unrealized losses/gains on investments	(119)	(922)	308	(1,991)
Change in non-credit component of impairment losses on investments	(1)	(1)	(3)	(2)
Change in net unrealized gains/losses on cash flow hedges	4	3	15	6
Change in net periodic pension and postretirement costs	3	9	5	16
Change in future policy benefits	(3)	8	(1)	17
Foreign currency translation adjustments	0	(5)	2	(8)
Other comprehensive (loss) income	(116)	(908)	326	(1,962)
Net (income) loss attributable to noncontrolling interests	(3)	3	(18)	13
Other comprehensive loss (income) attributable to noncontrolling interests	0	3	(2)	8
Total shareholders’ comprehensive income	$ 1,737	$ 732	$ 4,166	$ 1,472

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Operating activities
Net income	$ 3,860	$ 3,413
Adjustments to reconcile net income to net cash provided by operating activities:
Net losses on financial instruments	234	382
Equity in net earnings of other invested assets	73	(258)
Depreciation and amortization	895	751
Deferred income taxes	(393)	(181)
Share-based compensation	139	122
Changes in operating assets and liabilities:
Receivables, net	(299)	(662)
Other invested assets	(42)	32
Other assets	(529)	(412)
Policy liabilities	583	1,548
Unearned income	3,346	(182)
Accounts payable and other liabilities	160	632
Income taxes	391	(159)
Other, net	1	(33)
Net cash provided by operating activities	8,419	4,993
Investing activities
Purchases of investments	(17,648)	(13,253)
Proceeds from sale of investments	5,339	7,140
Maturities, calls and redemptions from investments	10,656	4,347
Changes in securities lending collateral	145	(620)
Purchases of subsidiaries, net of cash acquired	(1,651)	(609)
Purchases of property and equipment	(651)	(549)
Other, net	(46)	(58)
Net cash used in investing activities	(3,856)	(3,602)
Financing activities
Net proceeds from commercial paper borrowings	90	250
Proceeds from long-term borrowings	2,574	1,300
Repayments of long-term borrowings	(1,908)	(943)
Proceeds from short-term borrowings	0	1,275
Repayments of Short-term Debt	(90)	(1,375)
Changes in securities lending payable	(145)	620
Changes in bank overdrafts	(500)	817
Repurchase and retirement of common stock	(1,268)	(1,169)
Cash dividends	(701)	(618)
Proceeds from issuance of common stock under employee stock plans	81	116
Taxes paid through withholding of common stock under employee stock plans	(99)	(88)
Other, net	5	10
Net cash (used in) provided by financing activities	(1,961)	195
Effect of foreign exchange rates on cash and cash equivalents	2	(10)
Change in cash and cash equivalents	2,604	1,576
Cash and cash equivalents at beginning of period	7,387	4,880
Cash and cash equivalents at end of period	$ 9,991	$ 6,456

Consolidated Statements Of Chan

Consolidated Statements Of Changes in Equity - USD ($) shares in Millions, $ in Millions	Total	Cumulative Effect, Period of Adoption, Adjustment	Cumulative Effect, Period of Adoption, Adjusted Balance	Common Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings [Member]	Retained Earnings [Member] Cumulative Effect, Period of Adoption, Adjustment	Retained Earnings [Member] Cumulative Effect, Period of Adoption, Adjusted Balance	Accumulated Other Comprehensive (Loss) Income [Member]	Noncontrolling Interest [Member]
Balance (in shares), Beginning at Dec. 31, 2021				241.8
Total shareholders' equity, Beginning Balance at Dec. 31, 2021				$ 2	$ 9,148	$ 27,142		$ 27,119	$ (197)
Total shareholders' equity, Beginning Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021							$ (23)
Noncontrolling interests, Beginning Balance at Dec. 31, 2021										$ 68
Total equity, Beginning Balance at Dec. 31, 2021	$ 36,163		$ 36,140
Total equity, Beginning Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021		$ (23)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' net income						1,789
Net Income (Loss) Attributable to Noncontrolling Interest										(10)
Net income	1,779
Shareholders' other comprehensive income (loss)									(1,049)
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest										(5)
Other Comprehensive Income (Loss), Net of Tax	(1,054)
Noncontrolling Interest [Abstract]
Noncontrolling Interest, Period Increase (Decrease)	3									3
Repurchase and retirement of common stock, shares				(1.2)
Repurchase and retirement of common stock	(545)			$ 0	(45)	(500)
Dividends					0
Dividends and dividend equivalents	(312)					(312)
Issuance of common stock under employee stock plans, net of related tax benefits, Shares				0.5
Issuance of common stock under employee stock plans, net of related tax benefits	39				39
Convertible debenture repurchases, conversions and tax adjustments	9				9
Balance (in shares), Ending at Mar. 31, 2022				241.1
Total shareholders' equity, Ending Balance at Mar. 31, 2022				$ 2	9,151	28,096			(1,246)
Noncontrolling interests, Ending Balance at Mar. 31, 2022										56
Total equity, Ending Balance at Mar. 31, 2022	36,059
Balance (in shares), Beginning at Dec. 31, 2021				241.8
Total shareholders' equity, Beginning Balance at Dec. 31, 2021				$ 2	9,148	27,142		27,119	(197)
Total shareholders' equity, Beginning Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021							$ (23)
Noncontrolling interests, Beginning Balance at Dec. 31, 2021										68
Total equity, Beginning Balance at Dec. 31, 2021	36,163		36,140
Total equity, Beginning Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021		$ (23)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' net income	3,426
Net Income (Loss) Attributable to Noncontrolling Interest	(13)
Net income	3,413
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest	(8)
Other Comprehensive Income (Loss), Net of Tax	$ (1,962)
Noncontrolling Interest [Abstract]
Repurchase and retirement of common stock, shares	(2.5)
Repurchase and retirement of common stock	$ (1,169)
Balance (in shares), Ending at Jun. 30, 2022				240
Total shareholders' equity, Ending Balance at Jun. 30, 2022				$ 2	9,134	28,847			(2,151)
Noncontrolling interests, Ending Balance at Jun. 30, 2022										55
Total equity, Ending Balance at Jun. 30, 2022	35,887
Balance (in shares), Beginning at Mar. 31, 2022				241.1
Total shareholders' equity, Beginning Balance at Mar. 31, 2022				$ 2	9,151	28,096			(1,246)
Noncontrolling interests, Beginning Balance at Mar. 31, 2022										56
Total equity, Beginning Balance at Mar. 31, 2022	36,059
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' net income	1,637					1,637
Net Income (Loss) Attributable to Noncontrolling Interest	(3)									(3)
Net income	1,634
Shareholders' other comprehensive income (loss)									(905)
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest	(3)									(3)
Other Comprehensive Income (Loss), Net of Tax	(908)
Noncontrolling Interest [Abstract]
Noncontrolling Interest, Period Increase (Decrease)	5									5
Repurchase and retirement of common stock, shares				(1.3)
Repurchase and retirement of common stock	(624)			$ 0	(48)	(576)
Dividends and dividend equivalents	(310)					(310)
Issuance of common stock under employee stock plans, net of related tax benefits, Shares				0.2
Issuance of common stock under employee stock plans, net of related tax benefits	111				111
Convertible debenture repurchases, conversions and tax adjustments	(80)				(80)
Balance (in shares), Ending at Jun. 30, 2022				240
Total shareholders' equity, Ending Balance at Jun. 30, 2022				$ 2	9,134	28,847			(2,151)
Noncontrolling interests, Ending Balance at Jun. 30, 2022										55
Total equity, Ending Balance at Jun. 30, 2022	35,887
Balance (in shares), Beginning at Dec. 31, 2022				238
Total shareholders' equity, Beginning Balance at Dec. 31, 2022	36,243			$ 2	9,084			29,647	(2,490)
Noncontrolling interests, Beginning Balance at Dec. 31, 2022	87									87
Total equity, Beginning Balance at Dec. 31, 2022	36,330		36,330
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' net income						1,989
Net Income (Loss) Attributable to Noncontrolling Interest										15
Net income	2,004
Shareholders' other comprehensive income (loss)									440
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest										2
Other Comprehensive Income (Loss), Net of Tax	442
Noncontrolling Interest [Abstract]
Repurchase and retirement of common stock, shares				(1.3)
Repurchase and retirement of common stock					(51)	(575)
Repurchase and retirement of common stock, including excise tax	(626)
Dividends and dividend equivalents	(354)					(354)
Issuance of common stock under employee stock plans, net of related tax benefits, Shares				0.4
Issuance of common stock under employee stock plans, net of related tax benefits	6				6	0
Convertible debenture repurchases, conversions and tax adjustments	(342)				(342)
Balance (in shares), Ending at Mar. 31, 2023				237.1
Total shareholders' equity, Ending Balance at Mar. 31, 2023				$ 2	8,697	30,707			(2,050)
Noncontrolling interests, Ending Balance at Mar. 31, 2023										104
Total equity, Ending Balance at Mar. 31, 2023	37,460
Balance (in shares), Beginning at Dec. 31, 2022				238
Total shareholders' equity, Beginning Balance at Dec. 31, 2022	36,243			$ 2	9,084			$ 29,647	(2,490)
Noncontrolling interests, Beginning Balance at Dec. 31, 2022	87									87
Total equity, Beginning Balance at Dec. 31, 2022	36,330		$ 36,330
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' net income	3,842
Net Income (Loss) Attributable to Noncontrolling Interest	18
Net income	3,860
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest	2
Other Comprehensive Income (Loss), Net of Tax	$ 326
Noncontrolling Interest [Abstract]
Repurchase and retirement of common stock, shares	(2.7)
Repurchase and retirement of common stock	$ (1,268)
Balance (in shares), Ending at Jun. 30, 2023				235.9
Total shareholders' equity, Ending Balance at Jun. 30, 2023	38,205			$ 2	8,761	31,608			(2,166)
Noncontrolling interests, Ending Balance at Jun. 30, 2023	107									107
Total equity, Ending Balance at Jun. 30, 2023	38,312
Balance (in shares), Beginning at Mar. 31, 2023				237.1
Total shareholders' equity, Beginning Balance at Mar. 31, 2023				$ 2	8,697	30,707			(2,050)
Noncontrolling interests, Beginning Balance at Mar. 31, 2023										104
Total equity, Beginning Balance at Mar. 31, 2023	37,460
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' net income	1,853					1,853
Net Income (Loss) Attributable to Noncontrolling Interest	3									3
Net income	1,856
Shareholders' other comprehensive income (loss)									(116)
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest	0									0
Other Comprehensive Income (Loss), Net of Tax	(116)
Noncontrolling Interest [Abstract]
Repurchase and retirement of common stock, shares				(1.4)
Repurchase and retirement of common stock	(652)				(52)	(600)
Dividends and dividend equivalents	(352)					(352)
Issuance of common stock under employee stock plans, net of related tax benefits, Shares				0.2
Issuance of common stock under employee stock plans, net of related tax benefits	116				116
Balance (in shares), Ending at Jun. 30, 2023				235.9
Total shareholders' equity, Ending Balance at Jun. 30, 2023	38,205			$ 2	$ 8,761	$ 31,608			$ (2,166)
Noncontrolling interests, Ending Balance at Jun. 30, 2023	107									$ 107
Total equity, Ending Balance at Jun. 30, 2023	$ 38,312

Organization

Organization	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico unless the context otherwise requires. Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in terms of medical membership, serving approximately 48 million medical members through our affiliated health plans as of June 30, 2023. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Employer Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management, wellness programs, actuarial services and other administrative services. We provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to customers of our subsidiary health plans and also unaffiliated health plans, including pharmacy services and dental, vision, life, disability and supplemental health insurance benefits, as well as integrated health services. We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (with the exception of 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also serve members in numerous states as Amerigroup, Freedom Health, HealthLink, HealthSun, MMM, Optimum HealthCare, Simply Healthcare, UniCare and/or Wellpoint. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries. Through various subsidiaries, we also offer pharmacy services as CarelonRx and other healthcare-related services as Carelon Services, Aspire Health, Carelon Behavioral Health and CareMore. As we announced in 2022, over the next several years we are organizing our brand portfolio into the following core go-to-market brands: • Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans; and • Wellpoint — we are uniting select non-BCBSA licensed Medicare, Medicaid and commercial plans under the Wellpoint name; and • Carelon — this brand brings together our healthcare-related brands and capabilities, including our CarelonRx and Carelon Services businesses, under a single brand name. Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner. Given this evolution, we reviewed and modified how we manage our business, monitor our performance and allocate our resources, and made changes to our reportable segments beginning in the first quarter of 2023. The results of our operations are now reported in the following four reportable segments: Health Benefits (aggregates our previously reported Commercial & Specialty Business and Government Business segments), CarelonRx, Carelon Services (previously included in our Other segment) and Corporate & Other (our businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable

Basis Of Presentation and Signi

Basis Of Presentation and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation and Significant Accounting Policies Basis of Presentation: The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Annual Report on Form 10-K”) , unless the information contained in those disclosures materially changed or is required by GAAP. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three and six months ended June 30, 2023 and 2022 have been recorded. The results of operations for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2023, or any other period. The seasonal nature of portions of our health care and related benefits business, as well as competitive and other market conditions, may cause full-year results to differ from estimates based upon our interim results of operations. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2022 included in our 2022 Annual Report on Form 10-K. Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income. Cash and Cash Equivalents: We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $391 and $258 at June 30, 2023 and December 31, 2022, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets. Investments: We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity. If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss. The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default. For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income. The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations and are reported under the caption “Other invested assets” in our consolidated balance sheets. We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets. We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets. Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold. We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which is reported under the caption “Other current assets” on our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments. Receivables: Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts. Premium receivables include the uncollected amounts from employer risk-based groups, individuals and government programs for insurance services. Premium receivables are reported net of an allowance for doubtful accounts of $184 and $152 at June 30, 2023 and December 31, 2022, respectively. Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers for administrative services. Self-funded receivables are reported net of an allowance for doubtful accounts of $86 and $68 at June 30, 2023 and December 31, 2022, respectively. Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $816 and $744 at June 30, 2023 and December 31, 2022, respectively. Revenue Recognition: For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at June 30, 2023. For the three and six months ended June 30, 2023 and 2022, revenue recognized from performance obligations related to prior periods, such as changes in transaction price, were not material. For contracts that have an original, expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material. Recently Adopted Accounting Guidance: In November 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 change the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12”), which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. This standard requires us to review cash flow assumptions for our long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires us to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount our reserves for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of our liabilities. In addition, this standard changes the amortization method for deferred acquisition costs. We adopted these amendments on January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and deferred acquisition costs as of the transition date, January 1, 2021. While the adoption did not have an overall material impact, our prior period financial statements presented in this Form 10-Q have been restated to reflect the impacts of our adoption as required by the new standard. There were no other new accounting pronouncements that were issued or became effective since the issuance of our 2022 Annual Report on Form 10-K that had, or are expected to have, a material impact on our consolidated financial position, results of operations or cash flows.

Business Acquisitions

Business Acquisitions	6 Months Ended
	Jun. 30, 2023
Business Combinations [Abstract]
Business Acquisitions	Business Acquisitions and Divestitures Pending Divestiture On March 28, 2023, we announced our entrance into an agreement to sell our life and disability businesses to StanCorp Financial Group, Inc. (“The Standard”), a provider of financial protection products and services for employers and individuals. Upon closing, we and The Standard will enter into a product distribution partnership. The divestiture is expected to close by the end of the first quarter of 2024 and is subject to standard closing conditions and customary approvals. The related net assets held for sale and results of operations for the employee benefits businesses to be divested as of and for the three and six months ending June 30, 2023 were not material. Pending Acquisition On January 23, 2023, we announced our entrance into an agreement to acquire Louisiana Health Service & Indemnity Company, d/b/a Blue Cross and Blue Shield of Louisiana (“BCBSLA”), an independent licensee of the BCBSA that provides healthcare plans to the Individual, Employer Group, Medicaid and Medicare markets, primarily in the State of Louisiana. This acquisition aligns with our mission to become a lifetime, trusted health partner as we bring our innovative whole-health solutions to BCBSLA’s members. The acquisition is expected to close by the end of the fourth quarter of 2023 and is subject to standard closing conditions and customary approvals. Completed Acquisitions On February 15, 2023, we completed our acquisition of BioPlus Parent, LLC and subsidiaries (“BioPlus”) from CarepathRx Aggregator, LLC. Prior to the acquisition, BioPlus was one of the largest independent specialty pharmacy organizations in the United States. BioPlus, which operates as part of CarelonRx, seeks to connect payors and providers of specialty pharmaceuticals to meet the medication therapy needs of patients with complex medical conditions. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. As of June 30, 2023, the purchase price was allocated to the tangible and intangible net assets acquired based on management’s initial estimates of their fair values, of which $820 has been allocated to finite-lived intangible assets and $877 to goodwill, including an increase to goodwill for measurement period adjustments of $149 during the quarter ended June 30, 2023. The majority of goodwill is not deductible for income tax purposes. As of June 30, 2023, the initial accounting for the acquisition had not been finalized. The proforma effects of this acquisition for prior periods were not material to our consolidated results of operations. On May 5, 2022, we completed our acquisition of Integra Managed Care (“Integra”). Integra is a managed long-term care plan that serves New York state Medicaid members, enabling adults with long-term care needs and disabilities to live safely and independently in their own homes. The initial accounting for this acquisition was finalized as of June 30, 2023. The purchase price was allocated to tangible and intangible net assets acquired based on management’s estimates of their fair values, of which $89 has been allocated to finite-lived intangible assets, $250 to indefinite-lived intangible assets, and $139 to goodwill. Contractual purchase price adjustments during the quarter ended June 30, 2023 were $13 and resulted in an increase to goodwill. The majority of goodwill is deductible for income tax purposes. The proforma effects of this acquisition for prior periods were not material to our consolidated results of operations.

Investments

Investments	6 Months Ended
	Jun. 30, 2023
Investments [Abstract]
Investments	Investments Fixed Maturity Securities We evaluate our available-for-sale fixed maturity securities for declines based on qualitative and quantitative factors. We have established an allowance for credit loss and recorded credit loss expense as a reflection of our expected impairment losses. We continue to review our investment portfolios under our impairment review policy. Given the inherent uncertainty of changes in market conditions and the significant judgments involved, there is a continuing risk that declines in fair value may occur and additional material impairment losses for credit losses on investments may be recorded in future periods. A summary of current and long-term fixed maturity securities, available-for-sale, at June 30, 2023 and December 31, 2022 is as follows: Cost or Gross Gross Allowance Estimated June 30, 2023 Fixed maturity securities: United States Government securities $ 1,957 $ 1 $ (75) $ — $ 1,883 Government sponsored securities 94 1 (4) — 91 Foreign government securities 337 2 (41) (1) 297 States, municipalities and political subdivisions, tax-exempt 3,957 22 (207) — 3,772 Corporate securities 14,276 50 (997) (4) 13,325 Residential mortgage-backed securities 3,617 11 (313) — 3,315 Commercial mortgage-backed securities 2,262 2 (180) (2) 2,082 Other asset-backed securities 4,224 15 (208) — 4,031 Total fixed maturity securities $ 30,724 $ 104 $ (2,025) $ (7) $ 28,796 December 31, 2022 Fixed maturity securities: United States Government securities $ 1,502 $ 2 $ (103) $ — $ 1,401 Government sponsored securities 82 1 (5) — 78 Foreign government securities 321 1 (46) (2) 274 States, municipalities and political subdivisions, tax-exempt 4,389 19 (265) — 4,143 Corporate securities 13,721 31 (1,218) (5) 12,529 Residential mortgage-backed securities 2,978 9 (324) — 2,663 Commercial mortgage-backed securities 2,055 1 (176) (2) 1,878 Other asset-backed securities 3,967 12 (241) — 3,738 Total fixed maturity securities $ 29,015 $ 76 $ (2,378) $ (9) $ 26,704 Other asset-backed securities primarily consists of collateralized loan obligations and other debt securities. For fixed maturity securities in an unrealized loss position at June 30, 2023 and December 31, 2022, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position: Less than 12 Months 12 Months or Greater (Securities are whole amounts) Number of Estimated Gross Number of Estimated Gross June 30, 2023 Fixed maturity securities: United States Government securities 58 $ 1,019 $ (29) 48 $ 278 $ (46) Government sponsored securities 18 63 (2) 29 18 (2) Foreign government securities 97 56 (2) 224 186 (39) States, municipalities and political subdivisions, tax-exempt 702 1,278 (20) 925 1,598 (187) Corporate securities 2,051 4,323 (129) 3,216 6,910 (868) Residential mortgage-backed securities 642 1,251 (38) 1,286 1,714 (275) Commercial mortgage-backed securities 246 701 (28) 553 1,316 (152) Other asset-backed securities 348 1,258 (62) 827 2,265 (146) Total fixed maturity securities 4,162 $ 9,949 $ (310) 7,108 $ 14,285 $ (1,715) December 31, 2022 Fixed maturity securities: United States Government securities 61 $ 701 $ (40) 38 $ 442 $ (63) Government sponsored securities 39 73 (4) 6 5 (1) Foreign government securities 150 100 (10) 198 142 (36) States, municipalities and political subdivisions, tax-exempt 1,398 2,615 (147) 396 652 (118) Corporate securities 3,551 7,826 (549) 2,204 3,521 (669) Residential mortgage-backed securities 1,341 1,435 (121) 496 982 (203) Commercial mortgage-backed securities 457 1,082 (76) 324 719 (100) Other asset-backed securities 784 2,203 (124) 398 1,074 (117) Total fixed maturity securities 7,781 $ 16,035 $ (1,071) 4,060 $ 7,537 $ (1,307) Unrealized losses on our securities shown in the table above have not been recognized into income because, as of June 30, 2023, we do not intend to sell these investments and it is likely that we will not be required to sell these investments prior to their maturity or anticipated recovery. The declines in fair values are largely due to increasing interest rates driven by the higher rate of inflation and other market conditions. Allowances for credit losses have been recorded in the amounts of $7 and $9 at June 30, 2023 and December 31, 2022, respectively, for declines in fair value due to unfavorable changes in the credit quality characteristics that impact our assessment of collectability of principal and interest. The amortized cost and fair value of fixed maturity securities at June 30, 2023, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations. Amortized Estimated Due in one year or less $ 1,127 $ 1,118 Due after one year through five years 8,193 7,810 Due after five years through ten years 9,466 8,883 Due after ten years 6,059 5,588 Mortgage-backed securities 5,879 5,397 Total fixed maturity securities $ 30,724 $ 28,796 During the three and six months ended June 30, 2023, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of $9,675 and $15,085, respectively. During the three and six months ended June 30, 2022, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of $7,026 and $10,672, respectively. In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i) changes in the investment environment; (ii) expectation that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold. Equity Securities A summary of marketable equity securities at June 30, 2023 and December 31, 2022 is as follows: June 30, 2023 December 31, 2022 Equity securities: Exchange traded funds $ 166 $ 822 Common equity securities 31 43 Private equity securities 75 88 Total $ 272 $ 953 Other Invested Assets Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations, mortgage loans and the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. Financial information for certain of these investments is reported on a one or three month lag due to the timing of when we receive financial information from the companies. Investment Gains and Losses Net investment (losses) gains for the three and six months ended June 30, 2023 and 2022 are as follows: Three Months Ended June 30 Six Months Ended June 30 2023 2022 2023 2022 Net (losses) gains: Fixed maturity securities: Gross realized gains from sales $ 11 $ 16 $ 21 $ 36 Gross realized losses from sales (99) (176) (214) (254) Impairment losses recognized in income (3) (1) (10) (21) Net realized losses from sales of fixed maturity securities (91) (161) (203) (239) Equity securities: Unrealized gains (losses) recognized on equity securities still held at the end of the period 2 (83) (2) (154) Net realized gains (losses) recognized on equity securities sold during the period 1 (5) 4 (19) Net gains (losses) on equity securities 3 (88) 2 (173) Other investments: Gross gains 2 10 20 33 Gross losses (16) (15) (9) (44) Impairment losses recognized in income (26) (1) (29) (5) Net losses on other investments (40) (6) (18) (16) Net losses on investments $ (128) $ (255) $ (219) $ (428) Accrued Investment Income At June 30, 2023 and December 31, 2022, accrued investment income totaled $266 and $245, respectively. We recognize accrued investment income under the caption “Other receivables” on our consolidated balance sheets. Securities Lending Programs We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. The fair value of the collateral received at the time of the transactions amounted to $2,311 and $2,457 at June 30, 2023 and December 31, 2022, respectively. The value of the collateral represented 102% of the market value of the securities on loan at each of June 30, 2023 and December 31, 2022. We recognize the collateral as an asset under the caption “Other current assets” in our consolidated balance sheets, and we recognize a corresponding liability for the obligation to return the collateral to the borrower under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets. At June 30, 2023 and December 31, 2022, the remaining contractual maturity of our securities lending agreements included overnight and continuous transactions of cash for $2,237 and $2,221, respectively, of United States Government securities for $73 and $224, respectively, and of Residential Mortgage-Backed securities for $1 and $12, respectively.

Derivative Financial Instrument

Derivative Financial Instruments	6 Months Ended
	Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	Derivative Financial InstrumentsWe primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, swaptions, embedded derivatives and warrants. We also enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions. We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to the Secured Overnight Financing Rate (“SOFR”). Any amounts recognized for changes in fair value of these derivatives are included in the captions “Other current assets,” “Other noncurrent assets,” “Other current liabilities” or “Other noncurrent liabilities” in our consolidated balance sheets. The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other comprehensive loss, net of tax, was $214 and $229 at June 30, 2023 and December 31, 2022, respectively. During the three and six months ended months ended June 30, 2023 , we recognized net gains of $7 and net losses of $15, respectively, on non-hedging derivatives. During the three and six months ended months ended June 30, 2022 , we recognized net gains on non-hedging derivatives of $24 and $46, respectively. For additional information relating to the fair value of our derivative assets and liabilities, see Note 6, “Fair Value,” of this Form 10-Q.

Fair Value

Fair Value	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value	Fair Value Assets and liabilities recorded at fair value in our consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by FASB guidance for fair value measurements and disclosures, are as follows: Level Input Input Definition Level I Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date. Level II Inputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data at the measurement date. Level III Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. The following methods, assumptions and inputs were used to determine the fair value of each class of the following assets and liabilities recorded at fair value in our consolidated balance sheets: Cash equivalents: Cash equivalents primarily consist of highly rated money market funds with maturities of three months or less and are purchased daily at par value with specified yield rates. Due to the high ratings and short-term nature of the funds, we designate all cash equivalents as Level I. Fixed maturity securities, available-for-sale: Fair values of available-for-sale fixed maturity securities are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value to facilitate fair value measurements and disclosures. Level II securities primarily include corporate securities, securities from states, municipalities and political subdivisions, mortgage-backed securities, United States government securities, foreign government securities, and certain other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. We have controls in place to review the pricing services’ qualifications and procedures used to determine fair values. In addition, we periodically review the pricing services’ pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. We also have certain fixed maturity securities, primarily collateralized loan obligation securities and corporate debt securities, that are designated Level III securities. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets. Equity securities: Fair values of equity securities are generally designated as Level I and are based on quoted market prices. For certain equity securities, quoted market prices for the identical security are not always available, and the fair value is estimated by reference to similar securities for which quoted prices are available. These securities are designated Level II. We also have certain equity securities, including private equity securities, for which the fair value is estimated based on each security’s current condition and future cash flow projections. Such securities are designated Level III. The fair values of these private equity securities are generally based on either broker quotes or discounted cash flow projections using assumptions for inputs such as the weighted-average cost of capital, long-term revenue growth rates and earnings before interest, taxes, depreciation and amortization, and/or revenue multiples that are not observable in the markets. Securities lending collateral: Fair values of securities lending collateral are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value, to facilitate fair value measurements and disclosures. Derivatives: Fair values are based on the quoted market prices by the financial institution that is the counterparty to the derivative transaction. We independently verify prices provided by the counterparties using valuation models that incorporate observable market inputs for similar derivative transactions. Derivatives are designated as Level II securities. Derivatives presented within the fair value hierarchy table below are presented on a gross basis and not on a master netting basis by counterparty. A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at June 30, 2023 and December 31, 2022 is as follows: Level I Level II Level III Total June 30, 2023 Assets: Cash equivalents $ 6,100 $ — $ — $ 6,100 Fixed maturity securities, available-for-sale: United States Government securities — 1,883 — 1,883 Government sponsored securities — 91 — 91 Foreign government securities — 297 — 297 States, municipalities and political subdivisions, tax-exempt — 3,772 — 3,772 Corporate securities — 13,222 103 13,325 Residential mortgage-backed securities — 3,315 — 3,315 Commercial mortgage-backed securities — 2,082 — 2,082 Other asset-backed securities — 3,665 366 4,031 Total fixed maturity securities, available-for-sale — 28,327 469 28,796 Equity securities: Exchange traded funds 166 — — 166 Common equity securities 12 19 — 31 Private equity securities — — 75 75 Total equity securities 178 19 75 272 Other invested assets - common equity securities 121 — — 121 Securities lending collateral — 2,312 — 2,312 Derivatives - other assets — 3 — 3 Total assets $ 6,399 $ 30,661 $ 544 $ 37,604 Liabilities: Derivatives - other liabilities $ — $ (69) $ — $ (69) Total liabilities $ — $ (69) $ — $ (69) December 31, 2022 Assets: Cash equivalents $ 3,567 $ — $ — $ 3,567 Fixed maturity securities, available-for-sale: United States Government securities — 1,401 — 1,401 Government sponsored securities — 78 — 78 Foreign government securities — 274 — 274 States, municipalities and political subdivisions, tax-exempt — 4,143 — 4,143 Corporate securities — 12,392 137 12,529 Residential mortgage-backed securities — 2,663 — 2,663 Commercial mortgage-backed securities — 1,878 — 1,878 Other asset-backed securities — 3,382 356 3,738 Total fixed maturity securities, available-for-sale — 26,211 493 26,704 Equity securities: Exchange traded funds 822 — — 822 Common equity securities 2 41 — 43 Private equity securities — — 88 88 Total equity securities 824 41 88 953 Other invested assets - common equity securities 103 — — 103 Securities lending collateral — 2,457 — 2,457 Derivatives - other assets — 3 — 3 Total assets $ 4,494 $ 28,712 $ 581 $ 33,787 Liabilities: Derivatives - other liabilities $ — $ (60) $ — $ (60) Total liabilities $ — $ (60) $ — $ (60) A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the three months ended June 30, 2023 and 2022 is as follows: Corporate Residential Other Asset- Equity Total Three Months Ended June 30, 2023 Beginning balance at April 1, 2023 $ 142 $ — $ 390 $ 78 $ 610 Total gains (losses): Recognized in net income (2) — 1 2 1 Recognized in accumulated other comprehensive loss 1 — (9) — (8) Purchases 2 — 7 — 9 Sales (10) — (5) (5) (20) Settlements (4) — — — (4) Transfers into Level III — — 6 — 6 Transfers out of Level III (26) — (24) — (50) Ending balance at June 30, 2023 $ 103 $ — $ 366 $ 75 $ 544 Change in unrealized losses included in net income related to assets still held at June 30, 2023 $ — $ — $ — $ 1 $ 1 Three Months Ended June 30, 2022 Beginning balance at April 1, 2022 $ 341 $ 4 $ 37 $ 99 $ 481 Total gains (losses): Recognized in net income (5) — — (2) (7) Purchases 11 — 190 11 212 Sales (188) — — (14) (202) Settlements (5) — — — (5) Transfers into Level III 14 — — — 14 Transfers out of Level III (13) (4) (9) — (26) Ending balance at June 30, 2022 $ 155 $ — $ 218 $ 94 $ 467 Change in unrealized gains included in net income related to assets still held at June 30, 2022 $ — $ — $ — $ (3) $ (3) A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the six months ended June 30, 2023 and 2022 is as follows: Corporate Residential Other Asset- Equity Total Six Months Ended June 30, 2023 Beginning balance at January 1, 2023 $ 137 $ — $ 356 $ 88 $ 581 Total losses: Recognized in net income (3) — 1 (5) (7) Recognized in accumulated other comprehensive loss 2 — (4) — (2) Purchases 4 — 18 1 23 Sales (10) — (11) (9) (30) Settlements (6) — — — (6) Transfers into Level III — — 6 — 6 Transfers out of Level III (21) — — — (21) Ending balance at June 30, 2023 $ 103 $ — $ 366 $ 75 $ 544 Change in unrealized gains included in net income related to assets still held at June 30, 2023 $ — $ — $ — $ (6) $ (6) Six Months Ended June 30, 2022 Beginning balance at January 1, 2022 $ 336 $ 5 $ 19 $ 89 $ 449 Total gains: Recognized in net income (4) — — 1 (3) Recognized in accumulated other comprehensive loss (2) — — — (2) Purchases 35 — 205 20 260 Sales (175) — — (16) (191) Settlements (39) — — — (39) Transfers into Level III 14 — — — 14 Transfers out of Level III (10) (5) (6) — (21) Ending balance at June 30, 2022 $ 155 $ — $ 218 $ 94 $ 467 Change in unrealized gains included in net income related to assets still held at June 30, 2022 $ — $ — $ — $ 1 $ 1 There were no individually material transfers into or out of Level III during the three and six months ended June 30, 2023 or 2022. Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, “Business Acquisitions and Divestitures,” we completed our acquisition of BioPlus in the first quarter of 2023 and Integra during the second quarter of 2022. The net assets acquired in our acquisitions of BioPlus and Integra and resulting goodwill and other intangible assets were recorded at fair value primarily using Level III inputs. The majority of tangible assets acquired and liabilities assumed were recorded at their carrying values as of the acquisition date, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in our acquisitions of BioPlus and Integra were internally estimated based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets could be expected to generate in the future. We developed internal estimates for the expected cash flows and discount rate in the present value calculation. Other than the assets acquired and liabilities assumed in our acquisitions of BioPlus and Integra described above, there were no material assets or liabilities measured at fair value on a nonrecurring basis during the three and six months ended June 30, 2023 or 2022. Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our policy is to obtain quoted market prices in active markets to estimate fair values for recognition and disclosure purposes. Where quoted market prices in active markets are not available, fair values are estimated using discounted cash flow analyses, broker quotes, unobservable inputs or other valuation techniques. These techniques are significantly affected by our assumptions, including discount rates and estimates of future cash flows. The use of assumptions for unobservable inputs for the determination of fair value involves a level of judgment and uncertainty. Changes in assumptions that reasonably could have been different at the reporting date may result in a higher or lower determination of fair value. Changes in fair value measurements, if significant, may affect performance of cash flows. Potential taxes and other transaction costs are not considered in estimating fair values. Our valuation policy is generally to obtain quoted prices for each security from third-party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. As we are responsible for the determination of fair value, we perform analysis on the prices received from the pricing services to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our internal treasury personnel who are familiar with our investment portfolios, the pricing services engaged and the valuation techniques and inputs used. Our analysis includes procedures such as a review of month-to-month price fluctuations and price comparisons to secondary pricing services. There were no adjustments to quoted market prices obtained from the pricing services during the three and six months ended June 30, 2023 or 2022. In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in our consolidated balance sheets. Non-financial instruments such as real estate, property and equipment, other current assets, deferred income taxes, intangible assets and certain financial instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value. The carrying amounts reported in the consolidated balance sheets for cash, premium receivables, self-funded receivables, other receivables, unearned income, accounts payable and accrued expenses, and certain other current liabilities approximate fair value because of the short-term nature of these items. These assets and liabilities are not listed in the table below. The following methods and assumptions were used to estimate the fair value of each class of financial instrument that is recorded at its carrying value in our consolidated balance sheets: Other invested assets: Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations and mortgage loans, as well as the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. Mortgage loans are carried at amortized cost, which approximates fair value. The carrying value of corporate-owned life insurance policies represents the cash surrender value as reported by the respective insurer, which approximates fair value. Short-term borrowings: The fair value of our short-term borrowings is based on quoted market prices for the same or similar debt, or, if no quoted market prices were available, on the current market interest rates estimated to be available to us for debt of similar terms and remaining maturities. The carrying amount for commercial paper approximates fair value, as the underlying instruments have variable interest rates at market value. Long-term debt—senior unsecured notes and surplus notes: The fair values of our notes are based on quoted market prices in active markets for the same or similar debt, or, if no quoted market prices are available, on the current market observable rates estimated to be available to us for debt of similar terms and remaining maturities. Long-term debt—convertible debentures: The fair value of our convertible debentures is based on the quoted market price in the active private market in which the convertible debentures trade. A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at June 30, 2023 and December 31, 2022 is as follows: Carrying Estimated Fair Value Level I Level II Level III Total June 30, 2023 Assets: Other invested assets $ 5,872 $ — $ — $ 5,872 $ 5,872 Liabilities: Debt: Short-term borrowings 265 — 265 — 265 Notes 24,859 — 22,872 — 22,872 December 31, 2022 Assets: Other invested assets $ 5,582 $ — $ — $ 5,582 $ 5,582 Liabilities: Debt: Short-term borrowings 265 — 265 — 265 Notes 23,786 — 21,861 — 21,861 Convertible debentures 63 — 463 — 463

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes During the three months ended June 30, 2023 and 2022, we recognized income tax expense of $585 an d $488 (restated), respectively, which represent effective income tax rates of 24.0% and 23.0% (restated), respectively. The increase in our effective incom e tax rate from the three months ended June 30, 2022 is primarily due to the tax impact of expected geographic changes in our mix of 2023 earnings and reduced investment tax credits. During the six months ended June 30, 2023 and 2022, we recognized income tax expense of $1,200 an d $1,015 (restated), respectively, which represent effective income tax rates of 23.7% and 22.9% (restated), respectively. The increase in our effective incom e tax rate from the six months ended June 30, 2022 is primarily related to the tax impact of expected geographic changes in our mix of 2023 earnings and reduced investment tax credits. Income taxes receivable totaled $48 and $440 at June 30, 2023 and December 31, 2022, respectively. We recognize the income receivable as an asset under the caption “Other current assets” in our consolidated balance sheets.

Medical Claims Payable

Medical Claims Payable	6 Months Ended
	Jun. 30, 2023
Liability for Claims and Claims Adjustment Expense [Abstract]
Medical Claims payable	Medical Claims Payable A reconciliation of the beginning and ending balances for medical claims payable for the six months ended June 30, 2023 and 2022 is as follows: 2023 2022 Gross medical claims payable, beginning of period $ 15,348 $ 13,282 Ceded medical claims payable, beginning of period (6) (21) Net medical claims payable, beginning of period 15,342 13,261 Business combinations and purchase adjustments — 133 Net incurred medical claims: Current period 61,290 55,737 Prior periods redundancies (1,112) (972) Total net incurred medical claims 60,178 54,765 Net payments attributable to: Current period medical claims 48,217 42,882 Prior periods medical claims 11,409 10,401 Total net payments 59,626 53,283 Net medical claims payable, end of period 15,894 14,876 Ceded medical claims payable, end of period 8 13 Gross medical claims payable, end of period $ 15,902 $ 14,889 At June 30, 2023, the total of net incurred but not reported liabilities plus expected development on reported claims was $597, $2,224 and $13,073 for the claim years 2021 and prior, 2022 and 2023, respectively. The favorable development recognized in the six months ended June 30, 2023 and 2022 resulted primarily from trend factors in late 2022 and late 2021, respectively, developing more favorably than originally expected. Favorable development in the completion factors resulting from the latter parts of 2022 developing faster than expected also contributed to the favorable development in the six months ended June 30, 2023. The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for the periods in 2023 is as follows: Three Months Ended Six Months Ended June 30, 2023 March 31, 2023 June 30, 2023 Total net incurred medical claims $ 29,683 $ 30,495 $ 60,178 Quality improvement and other claims expense 1,103 1,109 2,212 Benefit expense $ 30,786 $ 31,604 $ 62,390 The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for the periods in 2022 is as follows: Three Months Ended Six Months Ended June 30, 2022 March 31, 2022 June 30, 2022 (Restated) (Restated) (Restated) Total net incurred medical claims $ 27,131 $ 27,634 $ 54,765 Quality improvement and other claims expense 1,100 1,161 2,261 Benefit expense $ 28,231 $ 28,795 $ 57,026 The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of June 30, 2023 and December 31, 2022, is as follows: June 30, 2023 December 31, 2022 Net medical claims payable, end of period $ 15,894 $ 15,342 Ceded medical claims payable, end of period 8 6 Insurance lines other than short duration 263 248 Gross medical claims payable, end of period $ 16,165 $ 15,596

Debt

Debt	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Debt	Debt We generally issue senior unsecured notes for long-term borrowing purposes. At June 30, 2023 and December 31, 2022, we had $24,834 and $23,761, respectively, outstanding under these notes. On February 8, 2023, we issued $500 aggregate principal amount of 4.900% Notes due 2026 (the “2026 Notes”), $1,000 aggregate principal amount of 4.750% Notes due 2033 (the “2033 Notes”), and $1,100 aggregate principal amount of 5.125% Notes due 2053 (the “2053 Notes”) under our shelf registration statement. Interest on the 2026 Notes is payable semi-annually in arrears on February 8 and August 8 of each year, commencing August 8, 2023. Interest on the 2033 Notes and 2053 Notes is payable semi-annually in arrears on February 15 and August 15 of each year, commencing August 15, 2023. We intend to use the proceeds for working capital and general corporate purposes, including, but not limited to, the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program. On January 17, 2023, we repaid, at maturity, the $1,000 outstanding balance of our 3.300% senior unsecured notes. On March 15, 2023, we repaid, at maturity, the $500 outstanding balance of our 0.450% senior unsecured notes. We have an unsecured surplus note with an outstanding principal balance of $25 at both June 30, 2023 and December 31, 2022. We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes. The 5-Year Facility provides credit of up to $4,000 and matures in April 2027. Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility. As of June 30, 2023, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.6%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of June 30, 2023, we were in compliance with all of our debt covenants under the 5-Year Facility. There were no amounts outstanding under the 5-Year Facility at any time during the six months ended June 30, 2023 or the year ended December 31, 2022. Through certain subsidiaries, we had previously entered into multiple 364-day lines of credit (the “Subsidiary Credit Facilities”) with separate lenders for general corporate purposes. The Subsidiary Credit Facilities provided combined credit of up to $200. As of June 30, 2023, the Subsidiary Credit Facilities have been terminated. We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general corporate purposes. At June 30, 2023 and December 31, 2022, we had $90 and $0, respectively, outstanding under this program. Beginning June 30, 2023, we have reclassified our commercial paper balances from long-term debt to short-term debt as our intent is to not replace short-term commercial paper outstanding at expiration with additional short-term commercial paper for an uninterrupted period extending for more than one year. On March 15, 2023, we redeemed all of our outstanding senior unsecured convertible debentures due 2042 (the “Debentures”), pursuant to the indenture dated as of October 9, 2012 between us and The Bank of New York Mellon Trust Company, N.A., as trustee. The Debentures were redeemed at a redemption price equal to 100% of the principal amount of the Debentures plus accrued and unpaid interest to, but excluding, the date of redemption, for cash totaling $5. During the three months ended March 31, 2023, $59 of aggregate principal amount of the Debentures was surrendered for conversion by certain holders in accordance with the terms and conditions of the indenture. We elected to settle the excess of the principal amount of the conversions with cash for total payments during the three months ended March 31, 2023 of $404. We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively, the “FHLBs”). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. We had $175 and $265 of outstanding short-term borrowings from the FHLBs at June 30, 2023 and December 31, 2022, respectively. All debt is a direct obligation of Elevance Health, Inc., except for the surplus note and the FHLBs borrowings.

Commitments And Contingencies

Commitments And Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments And Contingencies	Commitments and Contingencies Litigation and Regulatory Proceedings In the ordinary course of business, we are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint, or in other court filings, the amount of damages being sought, we have noted those alleged damages in the descriptions below. With respect to the cases described below, we contest liability and/or the amount of damages in each matter and believe we have meritorious defenses. Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In addition, even where loss is possible or an exposure to loss exists in excess of the liability already accrued with respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible loss or range of loss. With respect to many of the proceedings to which we are a party, we cannot provide an estimate of the possible losses, or the range of possible losses in excess of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings. For those legal proceedings where a loss is probable, or reasonably possible, and for which it is possible to reasonably estimate the amount of the possible loss or range of losses, we currently believe that the range of possible losses, in excess of established reserves is, in the aggregate, from $0 to approximately $250 at June 30, 2023. This estimated aggregate range of reasonably possible losses is based upon currently available information taking into account our best estimate of such losses for which such an estimate can be made. Blue Cross Blue Shield Antitrust Litigation We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees (the “Blue plans”) across the country. Cases filed in 28 states were consolidated into a single, multi-district proceeding captioned In re Blue Cross Blue Shield Antitrust Litigation that is pending in the U.S. District Court for the Northern District of Alabama (the “Court”). Generally, the suits allege that the BCBSA and the Blue plans have conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions, rules governing the BlueCard ® and National Accounts programs and other arrangements in violation of the Sherman Antitrust Act (“Sherman Act”) and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers. In April 2018, the Court issued an order on the parties’ cross motions for partial summary judgment, determining that the defendants’ aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard ® program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. With respect to whether the defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks, the Court found that summary judgment was not appropriate due to the existence of genuine issues of material fact. In April 2019, the plaintiffs filed motions for class certification, which defendants opposed. The BCBSA and Blue plans approved a settlement agreement and release with the subscriber plaintiffs (the “Subscriber Settlement Agreement”), which agreement required the Court’s approval to become effective. The Subscriber Settlement Agreement requires the defendants to make a monetary settlement payment and contains certain terms imposing non-monetary obligations including (i) eliminating the “national best efforts” rule in the BCBSA license agreements (which rule limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers with self-funded benefit plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue plan. In November 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following which members of the subscriber class were provided notice of the Subscriber Settlement Agreement and an opportunity to opt out of the class. A small number of subscribers submitted valid opt-outs by the opt-out deadline. In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the “Final Approval Order”). The Court amended its Final Approval Order in September 2022, further clarifying the injunctive relief that may be available to subscribers who submitted valid opt-outs. In compliance with the Subscriber Settlement Agreement, the Company paid $506 into an escrow account in September 2022, for an aggregate and full settlement payment by the Company of $596, which amount was accrued in 2020. Four notices of appeal of the Final Approval Order were filed prior to the September 2022 appeal deadline. Those appeals are proceeding in the United States Court of Appeals for the Eleventh Circuit, which has scheduled oral argument on the appeals for September 2023. In the event that all appellate rights are exhausted in a manner that affirms the Court’s Final Approval Order, the defendants’ payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective and the funds held in escrow will be distributed in accordance with the Subscriber Settlement Agreement. In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for class certification, which defendants opposed. In March 2021, the Court issued an order terminating the pending motion for class certification until the Court determined the standard of review applicable to the providers’ claims. In response to that order, the parties filed renewed standard of review motions in May 2021. In June 2021, the parties filed summary judgment motions not critically dependent on class certification. In February 2022, the Court issued orders (i) granting certain defendants’ motion for partial summary judgment against the provider plaintiffs who had previously released claims against such defendants, and (ii) granting the provider plaintiffs’ motion for partial summary judgment, determining that Ohio v. American Express Co . does not affect the standard of review in this case. In August 2022, the Court issued orders (i) granting in part the defendants’ motion regarding the antitrust standard of review, holding that for the period of time after the elimination of the “national best efforts” rule, the rule of reason applies to the provider plaintiffs’ market allocation conspiracy claims, and (ii) denying the provider plaintiffs’ motion for partial summary judgment on the standard of review, reaffirming its prior holding that the provider groups’ boycott claims are subject to the rule of reason. In November 2022, the Court issued an order requiring the parties to submit supplemental briefs on certain questions related to the providers’ renewed motion for class certification. We intend to continue to vigorously defend the provider litigation, which we believe is without merit; however, its ultimate outcome cannot be presently determined. A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed. Those actions are: Alaska Air Group, Inc., et al. v. Anthem, Inc., et al., No. 2:21-cv-01209-AMM (N.D. Ala.) ( "Alaska Air" ); JetBlue Airways Corp., et al. v. Anthem, Inc., et al. , No. 2:22-cv-00558-GMB (N.D. Ala.) ( "Jet Blue" ); Metropolitan Transportation Authority v. Blue Cross and Blue Shield of Alabama et al. , No. 2:22-cv-00265-RDP (N.D. Ala.); Bed Bath & Beyond Inc. v. Anthem, Inc. , No. 2:22-cv-01256-SGC (N.D. Ala.) ( "Bed Bath & Beyond" ); Hoover, et al. v. Blue Cross Blue Shield Association, et al. , No. 2:22-cv-00261-RDP (N.D. Ala.); and VHS Liquidating Trust v. Blue Cross of California, et al. , No. RG21106600 (Cal. Super.). In February 2023, the Court denied the defendants’ motion to dismiss based on a statute of limitations defense in Alaska Air and Jet Blue . In March 2023, pursuant to a stipulation by the parties, the Court denied the defendants’ motion to dismiss also based on a statute of limitations defense in Bed Bath & Beyond . We intend to continue to vigorously defend these follow-on cases, which we believe are without merit; however, their ultimate outcome cannot be presently determined. Blue Cross of California Taxation Litigation In July 2013, our California affiliate Blue Cross of California (doing business as Anthem Blue Cross) (“BCC”) was named as a defendant in a California taxpayer action filed in Los Angeles County Superior Court (the “Superior Court”) captioned Michael D. Myers v. State Board of Equalization, et al. This action was brought under a California statute that permits an individual taxpayer to sue a governmental agency when the taxpayer believes the agency has failed to enforce governing law. Plaintiff contends that BCC, a licensed Health Care Service Plan, is an “insurer” for purposes of taxation despite acknowledging it is not an “insurer” under regulatory law. At the time, under California law, “insurers” were required to pay a gross premiums tax (“GPT”) calculated as 2.35% on gross premiums. As a licensed Health Care Service Plan, BCC has paid the California Corporate Franchise Tax (“CFT”), the tax paid by California businesses generally. Plaintiff contends that BCC must pay the GPT rather than the CFT and seeks a writ of mandate directing the taxing agencies to collect the GPT and an order requiring BCC to pay GPT back taxes, interest, and penalties for the eight-year period prior to the filing of the complaint. Because the GPT is constitutionally imposed in lieu of certain other taxes, BCC has filed protective tax refund claims with the City of Los Angeles, the California Department of Health Care Services and the Franchise Tax Board to protect its rights to recover certain taxes previously paid should BCC eventually be determined to be subject to the GPT for the tax periods at issue in the litigation. In December 2020, the Superior Court granted BCC’s motion for summary judgment, dismissing the plaintiff’s lawsuit. In November 2021, the plaintiff appealed the summary judgment order. In March 2023, the appeal was argued before the California Second District Court of Appeal (the "Second District"). The Second District affirmed the Superior Court's summary judgment order in April 2023. The plaintiff filed a petition for review with the California Supreme Court in June 2023, and BCC filed its answer to the petition in the same month. We intend to continue to vigorously defend this suit, which we believe is without merit; however, the ultimate outcome cannot be presently determined. Express Scripts, Inc. Pharmacy Benefit Management Litigation In March 2016, we filed a lawsuit against Express Scripts, Inc. (“Express Scripts”), our vendor at the time for pharmacy benefit management services, captioned Anthem, Inc. v. Express Scripts, Inc. , in the U.S. District Court for the Southern District of New York (the “District Court”). The lawsuit seeks to recover over $14,800 in damages for pharmacy pricing that is higher than competitive benchmark pricing under the agreement between the parties (the “ESI Agreement”), over $158 in damages related to operational breaches, as well as various declarations under the ESI Agreement, including that Express Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms; (ii) was required to provide competitive benchmark pricing to us through the term of the ESI Agreement; (iii) has breached the ESI Agreement; and (iv) is required under the ESI Agreement to provide post-termination services, at competitive benchmark pricing, for one year following any termination. Express Scripts has disputed our contractual claims and is seeking declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI Agreement, and (ii) that it has no obligation to ensure that we receive any specific level of pricing, that we have no contractual right to any change in pricing under the ESI Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that we have been unjustly enriched by its payment of $4,675 at the time we entered into the ESI Agreement. In March 2017, the District Court granted our motion to dismiss Express Scripts’ counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. After such ruling, Express Scripts’ only remaining claims were for breach of contract and declaratory relief. In August 2021, Express Scripts filed a motion for summary judgment, which we opposed. In March 2022, the District Court granted in part and denied in part Express Scripts’ motion for summary judgment. The District Court dismissed our declaratory judgment claim, our breach of contract claim for failure to prove damages and most of our operational breach claims. As a result of the summary judgment decision, the only remaining claims as of the filing of this Quarterly Report on Form 10-Q are (i) our operational breach claim based on Express Scripts’ prior authorization processes and (ii) Express Scripts’ counterclaim for breach of the market check provision of the ESI Agreement. Express Scripts filed a second motion for summary judgment in June 2022, challenging our remaining operational breach claims, which we opposed, and the District Court denied in March 2023, allowing our operational breach claim to proceed. A trial date has been set for December 2023. We intend to appeal the earlier summary judgment decision at the appropriate time, vigorously pursue our claims and defend against counterclaims, which we believe are without merit; however, the ultimate outcome of this litigation cannot be presently determined. Medicare Risk Adjustment Litigation In March 2020, the U.S. Department of Justice (“DOJ”) filed a civil lawsuit against Elevance Health, Inc. in the U.S. District Court for the Southern District of New York (the “New York District Court”) in a case captioned United States v. Anthem, Inc . The DOJ’s suit alleges, among other things, that we falsely certified the accuracy of the diagnosis data we submitted to the Centers for Medicare and Medicaid Services (“CMS”) for risk-adjustment purposes under Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, we caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled us to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July 2020, alleging the same causes of action but revising some of its factual allegations. In September 2020, we filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain allegations in the amended complaint, all of which the New York District Court denied in October 2022. In November 2022, we filed an answer. In March 2023, discovery commenced, and an initial case management conference was held in April 2023. The Court entered a scheduling order requiring fact discovery to be completed by June 2024 and expert discovery to be complete by February 2025. We intend to continue to vigorously defend this suit, which we believe is without merit; however, the ultimate outcome cannot be presently determined. Investigations of CareMore and HealthSun With the assistance of outside counsel, we are conducting investigations of risk-adjustment practices involving data submitted to CMS (unrelated to our retrospective chart review program) at CareMore Health Plans, Inc. (“CareMore”), one of our California subsidiaries, and HealthSun Health Plans, Inc. (“HealthSun”), one of our Florida subsidiaries. Our CareMore investigation has resulted in the termination of CareMore’s relationship with one contracted provider in California. Our HealthSun investigation has focused on risk adjustment practices initiated prior to our acquisition of HealthSun in December 2017 that continued after the acquisition. We have voluntarily self-disclosed the existence of both of our investigations to CMS and the Criminal and Civil Divisions of the DOJ. We are cooperating with the ongoing investigations of the Criminal and Civil Divisions of the DOJ related to these risk adjustment practices, and have entered into a tolling agreement with the Civil Division of the DOJ related to its investigation. We have submitted corrected data to CMS related to these investigations. We have also asserted indemnity claims for escrowed funds under the HealthSun purchase agreement for, among other things, breach of healthcare and financial representation provisions, based on the conduct discovered during our investigation. While certain elements of the indemnity claims were resolved in the fourth quarters of 2021 and 2022, litigation in the Delaware Court of Chancery related to the remaining indemnity claims for escrowed funds remains ongoing. Other Contingencies From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. We, like Health Maintenance Organizations (“HMOs”) and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, Preferred Provider Organizations and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims. In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the character incidental to our business and are from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations. Contractual Obligations and Commitments In March 2020, we entered into an agreement with a vendor for information technology infrastructure and related management and support services through June 2025. The agreement superseded certain prior agreements for such services and includes provisions for additional services not provided under those agreements. Our remaining commitment under this agreement at June 30, 2023 is approximately $621. We will have the ability to terminate the agreement upon the occurrence of certain events, subject to early termination fees. We formed CarelonRx, formerly known as IngenioRx, to market and offer pharmacy services to our affiliated health plan customers, as well as to external customers outside of the health plans we own, starting in the second quarter of 2019. The comprehensive pharmacy services portfolio includes, but is not limited to, formulary management, pharmacy networks, specialty and home delivery pharmacy services and member services. CarelonRx delegates certain pharmacy services, such as claims processing and prescription fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement, which is set to terminate on December 31, 2024. With CarelonRx, we retain the responsibilities for clinical and formulary strategy and development, member and employer experiences, operations, sales, marketing, account management and retail network strategy.

Capital Stock

Capital Stock	6 Months Ended
	Jun. 30, 2023
Banking Regulation, Total Capital [Abstract]
Capital Stock	Capital Stock Use of Capital – Dividends and Stock Repurchase Program We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors. A summary of our cash dividend activity for the six months ended June 30, 2023 and 2022 is as follows: Declaration Date Record Date Payment Date Cash Dividend per Share Total Six Months Ended June 30, 2023 January 24, 2023 March 10, 2023 March 24, 2023 $1.48 $ 351 April 18, 2023 June 9, 2023 June 23, 2023 $1.48 $ 350 Six Months Ended June 30, 2022 January 25, 2022 March 10, 2022 March 25, 2022 $1.28 $ 309 April 19, 2022 June 10, 2022 June 24, 2022 $1.28 $ 309 On July 18, 2023, our Audit Committee declared a third quarter 2023 dividend to shareholders of $1.48 per share, payable on September 22, 2023 to shareholders of record at the close of business on September 8, 2023. Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On January 24, 2023, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to the common stock repurchase program. No duration has been placed on the common stock repurchase program, and we reserve the right to discontinue the program at any time. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are affected from time to time in the open market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase program is discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings. A summary of common stock repurchases for the six months ended June 30, 2023 and 2022 is as follows: Six Months Ended June 30 2023 2022 Shares repurchased 2.7 2.5 Average price per share $ 466.62 $ 471.72 Aggregate cost $ 1,268 $ 1,169 Authorization remaining at the end of the period $ 5,608 $ 3,022 For additional information regarding the use of capital for debt security repurchases, see Note 9, “Debt,” included in this Form 10-Q and Note 13, “Debt,” to our audited consolidated financial statements as of and for the year ended December 31, 2022 included in our 2022 Annual Report on Form 10-K. Stock Incentive Plan s A summary of stock option activity for the six months ended June 30, 2023 is as follows: Number of Weighted- Weighted- Aggregate Outstanding at January 1, 2023 2.8 $ 293.28 Granted 0.6 469.05 Exercised (0.2) 268.35 Forfeited or expired — 391.44 Outstanding at June 30, 2023 3.2 323.85 6.51 $ 402 Exercisable at June 30, 2023 2.1 265.51 5.31 $ 376 A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the six months ended June 30, 2023 is as follows: Restricted Weighted- Nonvested at January 1, 2023 1.2 $ 357.21 Granted 0.6 469.60 Vested (0.6) 301.18 Forfeited — 405.25 Nonvested at June 30, 2023 1.2 422.67 During the six months ended June 30, 2023, we granted approximately 0.2 restricted stock units that are contingent upon us achieving earnings targets over the three-year period from 2023 to 2025. These grants have been included in the activity shown above but will be subject to adjustment at the end of 2025 based on results in the three-year period. Fair Value We use a binomial lattice valuation model to estimate the fair value of all stock options granted. For a more detailed discussion of our stock incentive plan fair value methodology, see Note 15, “Capital Stock,” to our audited consolidated financial statements as of and for the year ended December 31, 2022 included in our 2022 Annual Report on Form 10-K. The following weighted-average assumptions were used to estimate the fair values of options granted during the six months ended June 30, 2023 and 2022: Six Months Ended June 30 2023 2022 Risk-free interest rate 3.95 % 1.97 % Volatility factor 29.00 % 29.00 % Quarterly dividend yield 0.316 % 0.282 % Weighted-average expected life (years) 4.40 5.10 The following weighted-average fair values per option or share were determined for the six months ended June 30, 2023 and 2022: Six Months Ended June 30 2023 2022 Options granted during the period $ 127.13 $ 116.80 Restricted stock awards granted during the period 469.60 452.78

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	6 Months Ended
	Jun. 30, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss A reconciliation of the components of accumulated other comprehensive loss at June 30, 2023 and 2022 is as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 (Restated) (Restated) Net unrealized investment (losses) gains: Beginning of period balance $ (1,330) $ (570) $ (1,755) $ 494 Other comprehensive (loss) gain before reclassifications, net of tax benefit (expense) of $61, $323, $(25) and $677, respectively (191) (1,050) 146 (2,196) Amounts reclassified from accumulated other comprehensive loss, net of tax expense of $(23), $(34), $(51) and $(55), respectively 72 128 162 205 Other comprehensive (loss) income (119) (922) 308 (1,991) Other comprehensive loss (income) attributable to noncontrolling interests, net of tax benefit (expense) of $0, $(1), $0 and $(3), respectively — 3 (2) 8 End of period balance (1,449) (1,489) (1,449) (1,489) Non-credit components of impairments on investments: Beginning of period balance (5) (1) (3) — Other comprehensive loss, net of tax benefit of $0, $0, $1 and $1, respectively (1) (1) (3) (2) End of period balance (6) (2) (6) (2) Net cash flow hedges: Beginning of period balance (218) (236) (229) (239) Other comprehensive income, net of tax (expense) of $(1), $(1), $7 and $(2), respectively 4 3 15 6 End of period balance (214) (233) (214) (233) Pension and other postretirement benefits: Beginning of period balance (497) (422) (499) (429) Other comprehensive income, net of tax expense of $(1), $(4), $(2) and $(6), respectively 3 9 5 16 End of period balance (494) (413) (494) (413) Future policy benefits: Beginning of period balance 15 (10) 13 (19) Other comprehensive (loss) income, net of tax expense of $1, $0, $1 and $0, respectively (3) 8 (1) 17 End of period balance 12 (2) 12 (2) Foreign currency translation adjustments: Beginning of period balance (15) (7) (17) (4) Other comprehensive income (loss), net of tax benefit of $(5), $1, $(3) and $2, respectively — (5) 2 (8) End of period balance (15) (12) (15) (12) Total: Total beginning of period accumulated other comprehensive loss (2,050) (1,246) (2,490) (197) Total other comprehensive (loss) income, net of tax benefit (expense) of $32, $285, $(72), and $617, respectively (116) (908) 326 (1,962) Total other comprehensive loss (income) attributable to noncontrolling interests, net of tax benefit (expense) of $0, $(1), $0and $(3) respectively — 3 (2) 8 Total end of period accumulated other comprehensive loss $ (2,166) $ (2,151) $ (2,166) $ (2,151)

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Earnings Per Share	Earnings per Share The denominator for basic and diluted earnings per share for the three and six months ended June 30, 2023 and 2022 is as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 Denominator for basic earnings per share – weighted-average shares 236.6 240.7 237.0 241.0 Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures 1.2 2.7 1.7 2.9 Denominator for diluted earnings per share 237.8 243.4 238.7 243.9 During the three months ended June 30, 2023 and 2022, weighted-average shares related to certain stock options of 1.0 and 0.5 respectively, were excluded from the denominator for diluted earnings per share because the stock options were anti-dilutive. During the six months ended June 30, 2023 and 2022, weighted-average shares related to certain stock options of 0.7 and 0.4, respectively, were excluded from each of the denominators for diluted earnings per share because the stock options were anti-dilutive. During the three and six months ended June 30, 2023, we issued approximately 0.0 and 0.6 restricted stock units under our stock incentive plans, 0.0 and 0.2 of which vesting is contingent upon us meeting specified annual earnings targets for the three-year period of 2023 through 2025. During the three and six months ended months ended June 30, 2022, we issued approximately 0.0 and 0.5 restricted stock units under our stock incentive plans, 0.0 and 0.2 of which vesting is contingent upon us meeting specified annual earnings targets for the three-year period of 2022 through 2024. The contingent restricted stock units have been excluded from the denominators for diluted earnings per share and will be included only if and when the contingency is met.

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Segment Information	Segment Information As discussed in Note 1 “Organization”, we are reorganizing our brand portfolio into three core go-to-market brands over the next several years. Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner. Given this evolution, we reviewed and modified how we manage our business and the products in each of our operating segments, which has resulted in restructurings between some of our operating segments. As a result of these changes, we have changed our reportable segment presentation and its composition to reflect how we began managing our operations and monitoring performance, aligning strategies and allocating resources beginning on January 1, 2023. The results of our operations are now reported in the following four reportable segments: Health Benefits (aggregates our previously reported Commercial & Specialty Business and Government Business segments), CarelonRx, Carelon Services (previously included in our Other segment) and Corporate & Other. In 2022, we managed and presented our operations through the following four reportable segments: Commercial & Specialty Business, Government Business, CarelonRx and Other. Previously reported information throughout this Form 10-Q has been reclassified to conform to the new presentation. Our Health Benefits segment offers a comprehensive suite of health plans and services to our Individual, Employer Group risk-based, Employer Group fee-based, BlueCard ® , Medicare, Medicaid and FEHB program members. Our Health Benefits segment also includes our National Government Services business. The Health Benefits segment offers health products on a full-risk basis; provides a broad array of administrative managed care services to our fee-based customers; and provides a variety of specialty and other insurance products and services such as stop loss, dental, vision, life, disability and supplemental health insurance benefits. Our CarelonRx segment includes our pharmacy business. CarelonRx markets and offers pharmacy services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. CarelonRx offers a comprehensive pharmacy services portfolio, which includes services such as formulary management, pharmacy networks, specialty and home delivery pharmacy services and member services. Our Carelon Services segment is focused on lowering the cost and improving the quality of healthcare by enabling and creating new care delivery and payment models, with a special emphasis on serving those with complex and chronic conditions. Carelon Services offers a broad array of healthcare-related services and capabilities to internal and external customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity services and subrogation services, as well as health and wellness programs. Our Corporate & Other segment includes our businesses that do not individually meet the quantitative threshold for an operating segment, as well as corporate expenses not allocated to our other reportable segments. We define operating revenues to include premium income, product revenue and service fees. Operating revenues are derived from premiums and fees received, primarily from the sale and administration of health benefits and pharmacy products and services. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and operating expense. Affiliated revenues represent revenues or costs for services provided to our subsidiaries by CarelonRx and Carelon Services, in addition to certain back-office services provided by our international businesses, which are recorded at cost or management’s estimate of fair market value. These affiliated revenues are eliminated in consolidation. Financial data by reportable segment for the three months ended June 30, 2023 and 2022 is as follows: Carelon Health CarelonRx Carelon Total Corporate Eliminations Total Three Months Ended June 30, 2023 Premiums $ 36,233 $ — $ 429 $ 429 $ — $ (73) $ 36,589 Product revenue — 4,859 — 4,859 — — 4,859 Service fees 1,767 — 201 201 (39) — 1,929 Operating revenue - unaffiliated 38,000 4,859 630 5,489 (39) (73) 43,377 Operating revenue - affiliated — 3,607 2,811 6,418 326 (6,744) — Operating revenue - total $ 38,000 $ 8,466 $ 3,441 $ 11,907 $ 287 $ (6,817) $ 43,377 Operating gain (loss) $ 2,148 $ 496 $ 136 $ 632 $ (152) $ — $ 2,628 Three Months Ended June 30, 2022 Premiums $ 32,787 $ — $ 327 $ 327 $ — $ (38) $ 33,076 Product revenue — 3,568 — 3,568 — — 3,568 Service fees 1,609 — 220 220 9 — 1,838 Operating revenue - unaffiliated 34,396 3,568 547 4,115 9 (38) 38,482 Operating revenue - affiliated — 3,503 2,436 5,939 306 (6,245) — Operating revenue - total $ 34,396 $ 7,071 $ 2,983 $ 10,054 $ 315 $ (6,283) $ 38,482 Operating gain (loss) (restated) $ 1,781 $ 479 $ 113 $ 592 $ (27) $ — $ 2,346 Financial data by reportable segment for the six months ended June 30, 2023 and 2022 is as follows: Carelon Health CarelonRx Carelon Total Corporate Eliminations Total Six Months Ended June 30, 2023 Premiums $ 71,767 $ — $ 839 $ 839 $ — $ (149) $ 72,457 Product revenue — 8,881 — 8,881 — — 8,881 Service fees 3,513 — 408 408 16 — 3,937 Operating revenue - unaffiliated 75,280 8,881 1,247 10,128 16 (149) 85,275 Operating revenue - affiliated — 7,609 5,506 13,115 522 (13,637) — Operating revenue - total $ 75,280 $ 16,490 $ 6,753 $ 23,243 $ 538 $ (13,786) $ 85,275 Operating gain (loss) $ 4,307 $ 1,008 $ 345 $ 1,353 (201) — 5,459 Six Months Ended June 30, 2022 Premiums $ 65,250 $ — $ 693 $ 693 $ — $ (82) $ 65,861 Product revenue — 6,869 — 6,869 — — 6,869 Service fees 3,173 — 446 446 19 — 3,638 Operating revenue - unaffiliated 68,423 6,869 1,139 8,008 19 (82) 76,368 Operating revenue - affiliated — 6,885 4,792 11,677 569 (12,246) — Operating revenue - total $ 68,423 $ 13,754 $ 5,931 $ 19,685 $ 588 $ (12,328) $ 76,368 Operating gain (loss) (restated) $ 3,632 $ 877 $ 313 $ 1,190 $ (49) $ — $ 4,773 For segment reporting, we present all capitated risk arrangements on a gross basis; therefore, eliminations also include adjustments for unaffiliated capitated risk arrangements that are recognized on a net basis under GAAP, as well as affiliated eliminations. A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the three and six months ended June 30, 2023 and 2022 is as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 Reportable segments’ operating revenue 43,377 $ 38,482 $ 85,275 $ 76,368 Net investment income 416 381 803 741 Net losses on financial instruments (121) (231) (234) (382) Total revenues $ 43,672 $ 38,632 $ 85,844 $ 76,727 A reconciliation of income before income tax expense to reportable segments’ operating gain included in our consolidated statements of income for the three and six months ended June 30, 2023 and 2022 is as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 (Restated) (Restated) Income before income tax expense $ 2,441 $ 2,122 $ 5,060 $ 4,428 Net investment income (416) (381) (803) (741) Net losses on financial instruments 121 231 234 382 Interest expense 261 208 512 409 Amortization of other intangible assets 221 166 456 295 Reportable segments’ operating gain $ 2,628 $ 2,346 $ 5,459 $ 4,773

Leases

Leases	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Leases	Leases We lease office space and certain computer and related equipment using noncancellable operating leases. Our leases have remaining lease terms of 1 year to 11 years. The information related to our leases is as follows: Balance Sheet Location June 30, 2023 December 31, 2022 Operating Leases Right-of-use assets Other noncurrent assets $ 605 $ 604 Lease liabilities, current Other current liabilities 178 181 Lease liabilities, noncurrent Other noncurrent liabilities 717 751 Three Months Ended Six Months Ended 2023 2022 2023 2022 Lease Expense Operating lease expense $ 32 $ 33 $ 57 $ 65 Short-term and variable lease expense 16 11 29 24 Sublease income (1) (1) (2) (2) Total lease expense $ 47 $ 43 $ 84 $ 87 Other information Operating cash paid for amounts included in the measurement of lease liabilities, operating leases $ 54 $ 53 $ 105 $ 105 Right-of-use assets obtained in exchange for new lease liabilities, operating leases $ 18 $ 29 $ 40 $ 37 As of June 30, 2023 and December 31, 2022, the weighted average remaining lease term of our operating leases was 7 years for each period. The lease liabilities reflect a weighted average discount rate of 3.28% at June 30, 2023 and 2.98% at December 31, 2022. Future lease payments for noncancellable operating leases with initial or remaining terms of one year or more are as follows: 2023 (excluding the six months ended June 30, 2023) $ 110 2024 195 2025 162 2026 128 2027 93 Thereafter 329 Total future minimum payments 1,017 Less imputed interest 122 Total lease liabilities $ 895

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Pay vs Performance Disclosure
Shareholders' net income	$ 1,853	$ 1,637	$ 3,842	$ 3,426

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2023 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Ramiro Peru [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	Ramiro Peru, a member of our Board of Directors, adopted a stock trading plan on May 3, 2023, pursuant to which he may sell up to 753 shares of the Company’s common stock prior to April 22, 2024. This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended, and the Company’s policies regarding transactions in our securities.
Name	Ramiro Peru
Title	member of our Board of Directors
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	May 3, 2023
Arrangement Duration	355 days
Aggregate Available	753

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation: The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Annual Report on Form 10-K”) , unless the information contained in those disclosures materially changed or is required by GAAP. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three and six months ended June 30, 2023 and 2022 have been recorded. The results of operations for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2023, or any other period. The seasonal nature of portions of our health care and related benefits business, as well as competitive and other market conditions, may cause full-year results to differ from estimates based upon our interim results of operations. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2022 included in our 2022 Annual Report on Form 10-K.
Foreign Currency	Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income.
Cash and Cash Equivalents	Cash and Cash Equivalents: We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $391 and $258 at June 30, 2023 and December 31, 2022, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.
Investment, Policy	Investments: We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity. If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss. The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default. For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income. The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations and are reported under the caption “Other invested assets” in our consolidated balance sheets. We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets. We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets. Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold. We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which is reported under the caption “Other current assets” on our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.
Receivable	Receivables: Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts. Premium receivables include the uncollected amounts from employer risk-based groups, individuals and government programs for insurance services. Premium receivables are reported net of an allowance for doubtful accounts of $184 and $152 at June 30, 2023 and December 31, 2022, respectively. Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers for administrative services. Self-funded receivables are reported net of an allowance for doubtful accounts of $86 and $68 at June 30, 2023 and December 31, 2022, respectively. Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $816 and $744 at June 30, 2023 and December 31, 2022, respectively.
Revenue Recognition	Revenue Recognition: For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at June 30, 2023. For the three and six months ended June 30, 2023 and 2022, revenue recognized from performance obligations related to prior periods, such as changes in transaction price, were not material. For contracts that have an original, expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.
New Accounting Pronouncements	Recently Adopted Accounting Guidance: In November 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 change the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12”), which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. This standard requires us to review cash flow assumptions for our long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires us to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount our reserves for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of our liabilities. In addition, this standard changes the amortization method for deferred acquisition costs. We adopted these amendments on January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and deferred acquisition costs as of the transition date, January 1, 2021. While the adoption did not have an overall material impact, our prior period financial statements presented in this Form 10-Q have been restated to reflect the impacts of our adoption as required by the new standard.

Investments (Tables)

Investments (Tables)	6 Months Ended
	Jun. 30, 2023
Investments [Abstract]
Current and Long-Term Investments, Available-For-Sale	A summary of current and long-term fixed maturity securities, available-for-sale, at June 30, 2023 and December 31, 2022 is as follows: Cost or Gross Gross Allowance Estimated June 30, 2023 Fixed maturity securities: United States Government securities $ 1,957 $ 1 $ (75) $ — $ 1,883 Government sponsored securities 94 1 (4) — 91 Foreign government securities 337 2 (41) (1) 297 States, municipalities and political subdivisions, tax-exempt 3,957 22 (207) — 3,772 Corporate securities 14,276 50 (997) (4) 13,325 Residential mortgage-backed securities 3,617 11 (313) — 3,315 Commercial mortgage-backed securities 2,262 2 (180) (2) 2,082 Other asset-backed securities 4,224 15 (208) — 4,031 Total fixed maturity securities $ 30,724 $ 104 $ (2,025) $ (7) $ 28,796 December 31, 2022 Fixed maturity securities: United States Government securities $ 1,502 $ 2 $ (103) $ — $ 1,401 Government sponsored securities 82 1 (5) — 78 Foreign government securities 321 1 (46) (2) 274 States, municipalities and political subdivisions, tax-exempt 4,389 19 (265) — 4,143 Corporate securities 13,721 31 (1,218) (5) 12,529 Residential mortgage-backed securities 2,978 9 (324) — 2,663 Commercial mortgage-backed securities 2,055 1 (176) (2) 1,878 Other asset-backed securities 3,967 12 (241) — 3,738 Total fixed maturity securities $ 29,015 $ 76 $ (2,378) $ (9) $ 26,704
Aggregate Fair Value and Gross Unrealized Loss of Fixed Maturity Securities in an Unrealized Loss Position	For fixed maturity securities in an unrealized loss position at June 30, 2023 and December 31, 2022, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position: Less than 12 Months 12 Months or Greater (Securities are whole amounts) Number of Estimated Gross Number of Estimated Gross June 30, 2023 Fixed maturity securities: United States Government securities 58 $ 1,019 $ (29) 48 $ 278 $ (46) Government sponsored securities 18 63 (2) 29 18 (2) Foreign government securities 97 56 (2) 224 186 (39) States, municipalities and political subdivisions, tax-exempt 702 1,278 (20) 925 1,598 (187) Corporate securities 2,051 4,323 (129) 3,216 6,910 (868) Residential mortgage-backed securities 642 1,251 (38) 1,286 1,714 (275) Commercial mortgage-backed securities 246 701 (28) 553 1,316 (152) Other asset-backed securities 348 1,258 (62) 827 2,265 (146) Total fixed maturity securities 4,162 $ 9,949 $ (310) 7,108 $ 14,285 $ (1,715) December 31, 2022 Fixed maturity securities: United States Government securities 61 $ 701 $ (40) 38 $ 442 $ (63) Government sponsored securities 39 73 (4) 6 5 (1) Foreign government securities 150 100 (10) 198 142 (36) States, municipalities and political subdivisions, tax-exempt 1,398 2,615 (147) 396 652 (118) Corporate securities 3,551 7,826 (549) 2,204 3,521 (669) Residential mortgage-backed securities 1,341 1,435 (121) 496 982 (203) Commercial mortgage-backed securities 457 1,082 (76) 324 719 (100) Other asset-backed securities 784 2,203 (124) 398 1,074 (117) Total fixed maturity securities 7,781 $ 16,035 $ (1,071) 4,060 $ 7,537 $ (1,307)
Amortized Cost and Fair Value of Fixed Maturity Securities, By Contractual Maturity	The amortized cost and fair value of fixed maturity securities at June 30, 2023, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations. Amortized Estimated Due in one year or less $ 1,127 $ 1,118 Due after one year through five years 8,193 7,810 Due after five years through ten years 9,466 8,883 Due after ten years 6,059 5,588 Mortgage-backed securities 5,879 5,397 Total fixed maturity securities $ 30,724 $ 28,796
Investments In Equity Securities	A summary of marketable equity securities at June 30, 2023 and December 31, 2022 is as follows: June 30, 2023 December 31, 2022 Equity securities: Exchange traded funds $ 166 $ 822 Common equity securities 31 43 Private equity securities 75 88 Total $ 272 $ 953
Net Investment Gains (Losses)	Net investment (losses) gains for the three and six months ended June 30, 2023 and 2022 are as follows: Three Months Ended June 30 Six Months Ended June 30 2023 2022 2023 2022 Net (losses) gains: Fixed maturity securities: Gross realized gains from sales $ 11 $ 16 $ 21 $ 36 Gross realized losses from sales (99) (176) (214) (254) Impairment losses recognized in income (3) (1) (10) (21) Net realized losses from sales of fixed maturity securities (91) (161) (203) (239) Equity securities: Unrealized gains (losses) recognized on equity securities still held at the end of the period 2 (83) (2) (154) Net realized gains (losses) recognized on equity securities sold during the period 1 (5) 4 (19) Net gains (losses) on equity securities 3 (88) 2 (173) Other investments: Gross gains 2 10 20 33 Gross losses (16) (15) (9) (44) Impairment losses recognized in income (26) (1) (29) (5) Net losses on other investments (40) (6) (18) (16) Net losses on investments $ (128) $ (255) $ (219) $ (428)

Fair Value (Tables)

Fair Value (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis	A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at June 30, 2023 and December 31, 2022 is as follows: Level I Level II Level III Total June 30, 2023 Assets: Cash equivalents $ 6,100 $ — $ — $ 6,100 Fixed maturity securities, available-for-sale: United States Government securities — 1,883 — 1,883 Government sponsored securities — 91 — 91 Foreign government securities — 297 — 297 States, municipalities and political subdivisions, tax-exempt — 3,772 — 3,772 Corporate securities — 13,222 103 13,325 Residential mortgage-backed securities — 3,315 — 3,315 Commercial mortgage-backed securities — 2,082 — 2,082 Other asset-backed securities — 3,665 366 4,031 Total fixed maturity securities, available-for-sale — 28,327 469 28,796 Equity securities: Exchange traded funds 166 — — 166 Common equity securities 12 19 — 31 Private equity securities — — 75 75 Total equity securities 178 19 75 272 Other invested assets - common equity securities 121 — — 121 Securities lending collateral — 2,312 — 2,312 Derivatives - other assets — 3 — 3 Total assets $ 6,399 $ 30,661 $ 544 $ 37,604 Liabilities: Derivatives - other liabilities $ — $ (69) $ — $ (69) Total liabilities $ — $ (69) $ — $ (69) December 31, 2022 Assets: Cash equivalents $ 3,567 $ — $ — $ 3,567 Fixed maturity securities, available-for-sale: United States Government securities — 1,401 — 1,401 Government sponsored securities — 78 — 78 Foreign government securities — 274 — 274 States, municipalities and political subdivisions, tax-exempt — 4,143 — 4,143 Corporate securities — 12,392 137 12,529 Residential mortgage-backed securities — 2,663 — 2,663 Commercial mortgage-backed securities — 1,878 — 1,878 Other asset-backed securities — 3,382 356 3,738 Total fixed maturity securities, available-for-sale — 26,211 493 26,704 Equity securities: Exchange traded funds 822 — — 822 Common equity securities 2 41 — 43 Private equity securities — — 88 88 Total equity securities 824 41 88 953 Other invested assets - common equity securities 103 — — 103 Securities lending collateral — 2,457 — 2,457 Derivatives - other assets — 3 — 3 Total assets $ 4,494 $ 28,712 $ 581 $ 33,787 Liabilities: Derivatives - other liabilities $ — $ (60) $ — $ (60) Total liabilities $ — $ (60) $ — $ (60)
Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs	A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the three months ended June 30, 2023 and 2022 is as follows: Corporate Residential Other Asset- Equity Total Three Months Ended June 30, 2023 Beginning balance at April 1, 2023 $ 142 $ — $ 390 $ 78 $ 610 Total gains (losses): Recognized in net income (2) — 1 2 1 Recognized in accumulated other comprehensive loss 1 — (9) — (8) Purchases 2 — 7 — 9 Sales (10) — (5) (5) (20) Settlements (4) — — — (4) Transfers into Level III — — 6 — 6 Transfers out of Level III (26) — (24) — (50) Ending balance at June 30, 2023 $ 103 $ — $ 366 $ 75 $ 544 Change in unrealized losses included in net income related to assets still held at June 30, 2023 $ — $ — $ — $ 1 $ 1 Three Months Ended June 30, 2022 Beginning balance at April 1, 2022 $ 341 $ 4 $ 37 $ 99 $ 481 Total gains (losses): Recognized in net income (5) — — (2) (7) Purchases 11 — 190 11 212 Sales (188) — — (14) (202) Settlements (5) — — — (5) Transfers into Level III 14 — — — 14 Transfers out of Level III (13) (4) (9) — (26) Ending balance at June 30, 2022 $ 155 $ — $ 218 $ 94 $ 467 Change in unrealized gains included in net income related to assets still held at June 30, 2022 $ — $ — $ — $ (3) $ (3) A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the six months ended June 30, 2023 and 2022 is as follows: Corporate Residential Other Asset- Equity Total Six Months Ended June 30, 2023 Beginning balance at January 1, 2023 $ 137 $ — $ 356 $ 88 $ 581 Total losses: Recognized in net income (3) — 1 (5) (7) Recognized in accumulated other comprehensive loss 2 — (4) — (2) Purchases 4 — 18 1 23 Sales (10) — (11) (9) (30) Settlements (6) — — — (6) Transfers into Level III — — 6 — 6 Transfers out of Level III (21) — — — (21) Ending balance at June 30, 2023 $ 103 $ — $ 366 $ 75 $ 544 Change in unrealized gains included in net income related to assets still held at June 30, 2023 $ — $ — $ — $ (6) $ (6) Six Months Ended June 30, 2022 Beginning balance at January 1, 2022 $ 336 $ 5 $ 19 $ 89 $ 449 Total gains: Recognized in net income (4) — — 1 (3) Recognized in accumulated other comprehensive loss (2) — — — (2) Purchases 35 — 205 20 260 Sales (175) — — (16) (191) Settlements (39) — — — (39) Transfers into Level III 14 — — — 14 Transfers out of Level III (10) (5) (6) — (21) Ending balance at June 30, 2022 $ 155 $ — $ 218 $ 94 $ 467 Change in unrealized gains included in net income related to assets still held at June 30, 2022 $ — $ — $ — $ 1 $ 1
Carrying And Fair Values By Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet	A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at June 30, 2023 and December 31, 2022 is as follows: Carrying Estimated Fair Value Level I Level II Level III Total June 30, 2023 Assets: Other invested assets $ 5,872 $ — $ — $ 5,872 $ 5,872 Liabilities: Debt: Short-term borrowings 265 — 265 — 265 Notes 24,859 — 22,872 — 22,872 December 31, 2022 Assets: Other invested assets $ 5,582 $ — $ — $ 5,582 $ 5,582 Liabilities: Debt: Short-term borrowings 265 — 265 — 265 Notes 23,786 — 21,861 — 21,861 Convertible debentures 63 — 463 — 463

Medical Claims Payable (Tables)

Medical Claims Payable (Tables)	6 Months Ended
	Jun. 30, 2023
Liability for Claims and Claims Adjustment Expense [Abstract]
Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable	A reconciliation of the beginning and ending balances for medical claims payable for the six months ended June 30, 2023 and 2022 is as follows: 2023 2022 Gross medical claims payable, beginning of period $ 15,348 $ 13,282 Ceded medical claims payable, beginning of period (6) (21) Net medical claims payable, beginning of period 15,342 13,261 Business combinations and purchase adjustments — 133 Net incurred medical claims: Current period 61,290 55,737 Prior periods redundancies (1,112) (972) Total net incurred medical claims 60,178 54,765 Net payments attributable to: Current period medical claims 48,217 42,882 Prior periods medical claims 11,409 10,401 Total net payments 59,626 53,283 Net medical claims payable, end of period 15,894 14,876 Ceded medical claims payable, end of period 8 13 Gross medical claims payable, end of period $ 15,902 $ 14,889
Reconciliation of Net Incurred Medical Claims to Benefit Expense	The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for the periods in 2023 is as follows: Three Months Ended Six Months Ended June 30, 2023 March 31, 2023 June 30, 2023 Total net incurred medical claims $ 29,683 $ 30,495 $ 60,178 Quality improvement and other claims expense 1,103 1,109 2,212 Benefit expense $ 30,786 $ 31,604 $ 62,390 The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for the periods in 2022 is as follows: Three Months Ended Six Months Ended June 30, 2022 March 31, 2022 June 30, 2022 (Restated) (Restated) (Restated) Total net incurred medical claims $ 27,131 $ 27,634 $ 54,765 Quality improvement and other claims expense 1,100 1,161 2,261 Benefit expense $ 28,231 $ 28,795 $ 57,026
Reconciliation of Short Duration Medical Claims Payable to the Consolidated Medical Claims Payable	The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of June 30, 2023 and December 31, 2022, is as follows: June 30, 2023 December 31, 2022 Net medical claims payable, end of period $ 15,894 $ 15,342 Ceded medical claims payable, end of period 8 6 Insurance lines other than short duration 263 248 Gross medical claims payable, end of period $ 16,165 $ 15,596

Capital Stock (Tables)

Capital Stock (Tables)	6 Months Ended
	Jun. 30, 2023
Banking Regulation, Total Capital [Abstract]
Summary of Cash Dividend Activity	A summary of our cash dividend activity for the six months ended June 30, 2023 and 2022 is as follows: Declaration Date Record Date Payment Date Cash Dividend per Share Total Six Months Ended June 30, 2023 January 24, 2023 March 10, 2023 March 24, 2023 $1.48 $ 351 April 18, 2023 June 9, 2023 June 23, 2023 $1.48 $ 350 Six Months Ended June 30, 2022 January 25, 2022 March 10, 2022 March 25, 2022 $1.28 $ 309 April 19, 2022 June 10, 2022 June 24, 2022 $1.28 $ 309
Summary of Share Repurchases	A summary of common stock repurchases for the six months ended June 30, 2023 and 2022 is as follows: Six Months Ended June 30 2023 2022 Shares repurchased 2.7 2.5 Average price per share $ 466.62 $ 471.72 Aggregate cost $ 1,268 $ 1,169 Authorization remaining at the end of the period $ 5,608 $ 3,022
Summary of Stock Option Activity	A summary of stock option activity for the six months ended June 30, 2023 is as follows: Number of Weighted- Weighted- Aggregate Outstanding at January 1, 2023 2.8 $ 293.28 Granted 0.6 469.05 Exercised (0.2) 268.35 Forfeited or expired — 391.44 Outstanding at June 30, 2023 3.2 323.85 6.51 $ 402 Exercisable at June 30, 2023 2.1 265.51 5.31 $ 376
Summary of Nonvested Restricted Stock Activity Including Restricted Stock Units	A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the six months ended June 30, 2023 is as follows: Restricted Weighted- Nonvested at January 1, 2023 1.2 $ 357.21 Granted 0.6 469.60 Vested (0.6) 301.18 Forfeited — 405.25 Nonvested at June 30, 2023 1.2 422.67
Summary of Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted During the Periods	The following weighted-average assumptions were used to estimate the fair values of options granted during the six months ended June 30, 2023 and 2022: Six Months Ended June 30 2023 2022 Risk-free interest rate 3.95 % 1.97 % Volatility factor 29.00 % 29.00 % Quarterly dividend yield 0.316 % 0.282 % Weighted-average expected life (years) 4.40 5.10
Schedule of Weighted-Average Fair Values Determined for the Periods	The following weighted-average fair values per option or share were determined for the six months ended June 30, 2023 and 2022: Six Months Ended June 30 2023 2022 Options granted during the period $ 127.13 $ 116.80 Restricted stock awards granted during the period 469.60 452.78

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Jun. 30, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Reconciliation Of Components Of Accumulated Other Comprehensive Loss	A reconciliation of the components of accumulated other comprehensive loss at June 30, 2023 and 2022 is as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 (Restated) (Restated) Net unrealized investment (losses) gains: Beginning of period balance $ (1,330) $ (570) $ (1,755) $ 494 Other comprehensive (loss) gain before reclassifications, net of tax benefit (expense) of $61, $323, $(25) and $677, respectively (191) (1,050) 146 (2,196) Amounts reclassified from accumulated other comprehensive loss, net of tax expense of $(23), $(34), $(51) and $(55), respectively 72 128 162 205 Other comprehensive (loss) income (119) (922) 308 (1,991) Other comprehensive loss (income) attributable to noncontrolling interests, net of tax benefit (expense) of $0, $(1), $0 and $(3), respectively — 3 (2) 8 End of period balance (1,449) (1,489) (1,449) (1,489) Non-credit components of impairments on investments: Beginning of period balance (5) (1) (3) — Other comprehensive loss, net of tax benefit of $0, $0, $1 and $1, respectively (1) (1) (3) (2) End of period balance (6) (2) (6) (2) Net cash flow hedges: Beginning of period balance (218) (236) (229) (239) Other comprehensive income, net of tax (expense) of $(1), $(1), $7 and $(2), respectively 4 3 15 6 End of period balance (214) (233) (214) (233) Pension and other postretirement benefits: Beginning of period balance (497) (422) (499) (429) Other comprehensive income, net of tax expense of $(1), $(4), $(2) and $(6), respectively 3 9 5 16 End of period balance (494) (413) (494) (413) Future policy benefits: Beginning of period balance 15 (10) 13 (19) Other comprehensive (loss) income, net of tax expense of $1, $0, $1 and $0, respectively (3) 8 (1) 17 End of period balance 12 (2) 12 (2) Foreign currency translation adjustments: Beginning of period balance (15) (7) (17) (4) Other comprehensive income (loss), net of tax benefit of $(5), $1, $(3) and $2, respectively — (5) 2 (8) End of period balance (15) (12) (15) (12) Total: Total beginning of period accumulated other comprehensive loss (2,050) (1,246) (2,490) (197) Total other comprehensive (loss) income, net of tax benefit (expense) of $32, $285, $(72), and $617, respectively (116) (908) 326 (1,962) Total other comprehensive loss (income) attributable to noncontrolling interests, net of tax benefit (expense) of $0, $(1), $0and $(3) respectively — 3 (2) 8 Total end of period accumulated other comprehensive loss $ (2,166) $ (2,151) $ (2,166) $ (2,151)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Denominator for Basic and Diluted Earnings Per Share	The denominator for basic and diluted earnings per share for the three and six months ended June 30, 2023 and 2022 is as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 Denominator for basic earnings per share – weighted-average shares 236.6 240.7 237.0 241.0 Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures 1.2 2.7 1.7 2.9 Denominator for diluted earnings per share 237.8 243.4 238.7 243.9

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Financial Data By Reportable Segment	Financial data by reportable segment for the three months ended June 30, 2023 and 2022 is as follows: Carelon Health CarelonRx Carelon Total Corporate Eliminations Total Three Months Ended June 30, 2023 Premiums $ 36,233 $ — $ 429 $ 429 $ — $ (73) $ 36,589 Product revenue — 4,859 — 4,859 — — 4,859 Service fees 1,767 — 201 201 (39) — 1,929 Operating revenue - unaffiliated 38,000 4,859 630 5,489 (39) (73) 43,377 Operating revenue - affiliated — 3,607 2,811 6,418 326 (6,744) — Operating revenue - total $ 38,000 $ 8,466 $ 3,441 $ 11,907 $ 287 $ (6,817) $ 43,377 Operating gain (loss) $ 2,148 $ 496 $ 136 $ 632 $ (152) $ — $ 2,628 Three Months Ended June 30, 2022 Premiums $ 32,787 $ — $ 327 $ 327 $ — $ (38) $ 33,076 Product revenue — 3,568 — 3,568 — — 3,568 Service fees 1,609 — 220 220 9 — 1,838 Operating revenue - unaffiliated 34,396 3,568 547 4,115 9 (38) 38,482 Operating revenue - affiliated — 3,503 2,436 5,939 306 (6,245) — Operating revenue - total $ 34,396 $ 7,071 $ 2,983 $ 10,054 $ 315 $ (6,283) $ 38,482 Operating gain (loss) (restated) $ 1,781 $ 479 $ 113 $ 592 $ (27) $ — $ 2,346
Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income	A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the three and six months ended June 30, 2023 and 2022 is as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 Reportable segments’ operating revenue 43,377 $ 38,482 $ 85,275 $ 76,368 Net investment income 416 381 803 741 Net losses on financial instruments (121) (231) (234) (382) Total revenues $ 43,672 $ 38,632 $ 85,844 $ 76,727
Reconciliation Of Income Before Income Tax Expense To Reportable Segments Operating Gain Included In The Consolidated Statements Of Income	A reconciliation of income before income tax expense to reportable segments’ operating gain included in our consolidated statements of income for the three and six months ended June 30, 2023 and 2022 is as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 (Restated) (Restated) Income before income tax expense $ 2,441 $ 2,122 $ 5,060 $ 4,428 Net investment income (416) (381) (803) (741) Net losses on financial instruments 121 231 234 382 Interest expense 261 208 512 409 Amortization of other intangible assets 221 166 456 295 Reportable segments’ operating gain $ 2,628 $ 2,346 $ 5,459 $ 4,773

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Lessee, Operating Lease, Disclosure [Table Text Block]	The information related to our leases is as follows: Balance Sheet Location June 30, 2023 December 31, 2022 Operating Leases Right-of-use assets Other noncurrent assets $ 605 $ 604 Lease liabilities, current Other current liabilities 178 181 Lease liabilities, noncurrent Other noncurrent liabilities 717 751 Three Months Ended Six Months Ended 2023 2022 2023 2022 Lease Expense Operating lease expense $ 32 $ 33 $ 57 $ 65 Short-term and variable lease expense 16 11 29 24 Sublease income (1) (1) (2) (2) Total lease expense $ 47 $ 43 $ 84 $ 87 Other information Operating cash paid for amounts included in the measurement of lease liabilities, operating leases $ 54 $ 53 $ 105 $ 105 Right-of-use assets obtained in exchange for new lease liabilities, operating leases $ 18 $ 29 $ 40 $ 37
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Future lease payments for noncancellable operating leases with initial or remaining terms of one year or more are as follows: 2023 (excluding the six months ended June 30, 2023) $ 110 2024 195 2025 162 2026 128 2027 93 Thereafter 329 Total future minimum payments 1,017 Less imputed interest 122 Total lease liabilities $ 895

Organization (Details)

Organization (Details) medical_member in Millions	Jun. 30, 2023 medical_member county states
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of Medical Members | medical_member	48
Number of counties in the Kansas City area the Company does not serve | county	30
Number of states in which the Company is licensed to conduct insurance operations | states	50

Basis of Presentation and Signf

Basis of Presentation and Signficant Accounting Policies Basis of Presentation and Significant Acconting Policies (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Customer funds and cash and cash equivalents on deposit for regulatory requirements	$ 391	$ 258
Securities lending transactions, initial collateral percentage value	102%
Premium receivable, allowance for doubtful accounts	$ 184	152
Self-funded receivables, allowance for doubtful accounts	86	68
Allowance for doubtful accounts, other receivables	$ 816	$ 744

Business Acquisitions Business

Business Acquisitions Business Acquisition (Assets Liabilities Acquired) (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Goodwill	$ 25,274	$ 25,274	$ 24,383
Integra Managed Care [Member]
Business Acquisition [Line Items]
Finite-lived Intangible Assets Acquired		89
Indefinite-lived Intangible Assets Acquired		250
Goodwill, Acquired During Period		139
Goodwill, Purchase Accounting Adjustments	13
BioPlus
Business Acquisition [Line Items]
Finite-lived Intangible Assets Acquired	820
Goodwill, Acquired During Period		$ 877
Goodwill, Purchase Accounting Adjustments	$ 149

Investments (Current And Long-T

Investments (Current And Long-Term Fixed Maturity Securities, Available-For-Sale) (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]
Cost or Amortized Cost	$ 30,724	$ 29,015
Gross Unrealized Gains	104	76
Gross Unrealized Losses	(2,025)	(2,378)
Debt Securities, Available-for-Sale, Allowance for Credit Loss	(7)	(9)
Available-for-sale Securities	28,796	26,704
United States Government Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Cost or Amortized Cost	1,957	1,502
Gross Unrealized Gains	1	2
Gross Unrealized Losses	(75)	(103)
Debt Securities, Available-for-Sale, Allowance for Credit Loss	0	0
Available-for-sale Securities	1,883	1,401
Government Sponsored Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Cost or Amortized Cost	94	82
Gross Unrealized Gains	1	1
Gross Unrealized Losses	(4)	(5)
Debt Securities, Available-for-Sale, Allowance for Credit Loss	0	0
Available-for-sale Securities	91	78
Foreign Government Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Cost or Amortized Cost	337	321
Gross Unrealized Gains	2	1
Gross Unrealized Losses	(41)	(46)
Debt Securities, Available-for-Sale, Allowance for Credit Loss	(1)	(2)
Available-for-sale Securities	297	274
States, Municipalities And Political Subdivisions [Member]
Debt Securities, Available-for-sale [Line Items]
Cost or Amortized Cost	3,957	4,389
Gross Unrealized Gains	22	19
Gross Unrealized Losses	(207)	(265)
Debt Securities, Available-for-Sale, Allowance for Credit Loss	0	0
Available-for-sale Securities	3,772	4,143
Corporate Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Cost or Amortized Cost	14,276	13,721
Gross Unrealized Gains	50	31
Gross Unrealized Losses	(997)	(1,218)
Debt Securities, Available-for-Sale, Allowance for Credit Loss	(4)	(5)
Available-for-sale Securities	13,325	12,529
Residential Mortgage-Backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Cost or Amortized Cost	3,617	2,978
Gross Unrealized Gains	11	9
Gross Unrealized Losses	(313)	(324)
Debt Securities, Available-for-Sale, Allowance for Credit Loss	0	0
Available-for-sale Securities	3,315	2,663
Commercial Mortgage-Backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Cost or Amortized Cost	2,262	2,055
Gross Unrealized Gains	2	1
Gross Unrealized Losses	(180)	(176)
Debt Securities, Available-for-Sale, Allowance for Credit Loss	(2)	(2)
Available-for-sale Securities	2,082	1,878
Other Asset-Backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Cost or Amortized Cost	4,224	3,967
Gross Unrealized Gains	15	12
Gross Unrealized Losses	(208)	(241)
Debt Securities, Available-for-Sale, Allowance for Credit Loss	0	0
Available-for-sale Securities	$ 4,031	$ 3,738

Investments (Aggregate Fair Val

Investments (Aggregate Fair Value And Gross Unrealized Loss Of Fixed Maturity Securities In An Unrealized Loss Position) (Details) - Fixed Maturities [Member] securities in Millions, $ in Millions	Jun. 30, 2023 USD ($) securities	Dec. 31, 2022 USD ($) securities
Debt Securities, Available-for-sale [Line Items]
Number of securities, less than 12 months | securities	4,162	7,781
Estimated fair value, less than 12 months	$ 9,949	$ 16,035
Gross unrealized loss, less than 12 months	$ (310)	$ (1,071)
Number of securities, 12 months or greater | securities	7,108	4,060
Estimated fair value, 12 months or greater	$ 14,285	$ 7,537
Gross unrealized loss, 12 months or greater	$ (1,715)	$ (1,307)
United States Government Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Number of securities, less than 12 months | securities	58	61
Estimated fair value, less than 12 months	$ 1,019	$ 701
Gross unrealized loss, less than 12 months	$ (29)	$ (40)
Number of securities, 12 months or greater | securities	48	38
Estimated fair value, 12 months or greater	$ 278	$ 442
Gross unrealized loss, 12 months or greater	$ (46)	$ (63)
Government Sponsored Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Number of securities, less than 12 months | securities	18	39
Estimated fair value, less than 12 months	$ 63	$ 73
Gross unrealized loss, less than 12 months	$ (2)	$ (4)
Number of securities, 12 months or greater | securities	29	6
Estimated fair value, 12 months or greater	$ 18	$ 5
Gross unrealized loss, 12 months or greater	$ (2)	$ (1)
Foreign Government Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Number of securities, less than 12 months | securities	97	150
Estimated fair value, less than 12 months	$ 56	$ 100
Gross unrealized loss, less than 12 months	$ (2)	$ (10)
Number of securities, 12 months or greater | securities	224	198
Estimated fair value, 12 months or greater	$ 186	$ 142
Gross unrealized loss, 12 months or greater	$ (39)	$ (36)
States, Municipalities And Political Subdivisions [Member]
Debt Securities, Available-for-sale [Line Items]
Number of securities, less than 12 months | securities	702	1,398
Estimated fair value, less than 12 months	$ 1,278	$ 2,615
Gross unrealized loss, less than 12 months	$ (20)	$ (147)
Number of securities, 12 months or greater | securities	925	396
Estimated fair value, 12 months or greater	$ 1,598	$ 652
Gross unrealized loss, 12 months or greater	$ (187)	$ (118)
Corporate Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Number of securities, less than 12 months | securities	2,051	3,551
Estimated fair value, less than 12 months	$ 4,323	$ 7,826
Gross unrealized loss, less than 12 months	$ (129)	$ (549)
Number of securities, 12 months or greater | securities	3,216	2,204
Estimated fair value, 12 months or greater	$ 6,910	$ 3,521
Gross unrealized loss, 12 months or greater	$ (868)	$ (669)
Residential Mortgage-Backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Number of securities, less than 12 months | securities	642	1,341
Estimated fair value, less than 12 months	$ 1,251	$ 1,435
Gross unrealized loss, less than 12 months	$ (38)	$ (121)
Number of securities, 12 months or greater | securities	1,286	496
Estimated fair value, 12 months or greater	$ 1,714	$ 982
Gross unrealized loss, 12 months or greater	$ (275)	$ (203)
Commercial Mortgage-Backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Number of securities, less than 12 months | securities	246	457
Estimated fair value, less than 12 months	$ 701	$ 1,082
Gross unrealized loss, less than 12 months	$ (28)	$ (76)
Number of securities, 12 months or greater | securities	553	324
Estimated fair value, 12 months or greater	$ 1,316	$ 719
Gross unrealized loss, 12 months or greater	$ (152)	$ (100)
Other Asset-Backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Number of securities, less than 12 months | securities	348	784
Estimated fair value, less than 12 months	$ 1,258	$ 2,203
Gross unrealized loss, less than 12 months	$ (62)	$ (124)
Number of securities, 12 months or greater | securities	827	398
Estimated fair value, 12 months or greater	$ 2,265	$ 1,074
Gross unrealized loss, 12 months or greater	$ (146)	$ (117)

Investments (Amortized Cost And

Investments (Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity) (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]
Due in one year or less, Amortized Cost	$ 1,127
Due after one year through five years, Amortized Cost	8,193
Due after five years through ten years, Amortized Cost	9,466
Due after ten years, Amortized Cost	6,059
Mortgage-backed securities, Amortized Cost	5,879
Available-for-sale securities, Amortized Cost	30,724	$ 29,015
Due in one year or less, Estimated Fair Value	1,118
Due after one year through five years, Estimated Fair Value	7,810
Due after five years through ten years, Estimated Fair Value	8,883
Due after ten years, Estimated Fair Value	5,588
Mortgage-backed securities, Estimated Fair Value	5,397
Available-for-sale securities, Estimated Fair Value	$ 28,796	$ 26,704

Investments (Current Equity Sec

Investments (Current Equity Securities) (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Equity Securities [Line Items]
Equity securities	$ 272	$ 953
Exchange Traded Funds [Member]
Equity Securities [Line Items]
Equity securities	166	822
Common Equity Securities [Member]
Equity Securities [Line Items]
Equity securities	31	43
Private Equity Funds [Member]
Equity Securities [Line Items]
Equity securities	$ 75	$ 88

Investments (Net Investment Gai

Investments (Net Investment Gains/Losses) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Investment [Line Items]
Net losses on investments	$ (128)	$ (255)	$ (219)	$ (428)
Fixed Maturities [Member]
Investment [Line Items]
Debt Securities, Available-for-sale, Realized Gain	11	16	21	36
Debt Securities, Available-for-sale, Realized Loss	(99)	(176)	(214)	(254)
Impairment losses recognized in income	(3)	(1)	(10)	(21)
Debt Securities, Available-for-sale, Realized Gain (Loss)	(91)	(161)	(203)	(239)
Equity Securities [Member]
Investment [Line Items]
Unrealized gains (losses) recognized on equity securities still held at the end of the period	2	(83)	(2)	(154)
Net realized gains (losses) recognized on equity securities sold during the period	1	(5)	4	(19)
Net gains (losses) on equity securities	3	(88)	2	(173)
Other Investments [Member]
Investment [Line Items]
Gross gains	2	10	20	33
Gross losses	(16)	(15)	(9)	(44)
Impairment losses recognized in income	(26)	(1)	(29)	(5)
Net losses on other investments	$ (40)	$ (6)	$ (18)	$ (16)

Investments (Narrative) (Detail

Investments (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Schedule of Investments [Line Items]
Accrued investment income receivable	$ 266		$ 266		$ 245
Fair value of collateral received at time of securities lending transactions	$ 2,311		$ 2,311		$ 2,457
Securities lending transactions ratio of fair value of collateral held to fair value of securities loaned	102%		102%		102%
Debt Securities, Available-for-Sale, Allowance for Credit Loss	$ (7)		$ (7)		$ (9)
United States Government Securities [Member]
Schedule of Investments [Line Items]
Debt Securities, Available-for-Sale, Allowance for Credit Loss	0		0		0
Residential Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Debt Securities, Available-for-Sale, Allowance for Credit Loss	0		0		0
Fixed Maturities [Member]
Schedule of Investments [Line Items]
Proceeds from Sale of Available-for-sale Securities	9,675	$ 7,026	15,085	$ 10,672
Overnight and Continuous [Member] | Cash [Member]
Schedule of Investments [Line Items]
Collateral received for securities loaned, at carrying value	2,237		2,237		2,221
Overnight and Continuous [Member] | United States Government Securities [Member]
Schedule of Investments [Line Items]
Collateral received for securities loaned, at carrying value	73		73		224
Overnight and Continuous [Member] | Residential Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Collateral received for securities loaned, at carrying value	$ 1		$ 1		$ 12

Derivative Financial Instrume_2

Derivative Financial Instruments (Financial Statement Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Gain (Loss) Recognized	$ 7	$ 24	$ (15)	$ 46
Cash Flow Hedging [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax	$ (214)		$ (214)		$ (229)

Fair Value (Fair Value Measurem

Fair Value (Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis) (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 6,100	$ 3,567
Available-for-sale Securities	28,796	26,704
Other invested assets	5,993	5,685
Securities lending collateral	2,312	2,457
Total assets	37,604	33,787
Total liabilities	(69)	(60)
United States Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	1,883	1,401
Government Sponsored Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	91	78
Foreign Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	297	274
States, Municipalities And Political Subdivisions [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	3,772	4,143
Corporate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	13,325	12,529
Residential Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	3,315	2,663
Commercial Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	2,082	1,878
Other Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	4,031	3,738
Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	272	953
Equity Securities [Member] | Exchange Traded Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	166	822
Equity Securities [Member] | Common Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	31	43
Equity Securities [Member] | Private Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	75	88
Other Investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	5,872	5,582
Other Investments [Member] | Common Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	121	103
Derivatives [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	3	3
Derivative liabilities	(69)	(60)
Level I [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	6,100	3,567
Available-for-sale Securities	0	0
Securities lending collateral	0	0
Total assets	6,399	4,494
Total liabilities	0	0
Level I [Member] | United States Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level I [Member] | Government Sponsored Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level I [Member] | Foreign Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level I [Member] | States, Municipalities And Political Subdivisions [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level I [Member] | Corporate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level I [Member] | Residential Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level I [Member] | Commercial Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level I [Member] | Other Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level I [Member] | Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	178	824
Level I [Member] | Equity Securities [Member] | Exchange Traded Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	166	822
Level I [Member] | Equity Securities [Member] | Common Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	12	2
Level I [Member] | Equity Securities [Member] | Private Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	0	0
Level I [Member] | Other Investments [Member] | Common Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	121	103
Level I [Member] | Derivatives [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	0	0
Derivative liabilities	0	0
Level II [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Available-for-sale Securities	28,327	26,211
Securities lending collateral	2,312	2,457
Total assets	30,661	28,712
Total liabilities	(69)	(60)
Level II [Member] | United States Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	1,883	1,401
Level II [Member] | Government Sponsored Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	91	78
Level II [Member] | Foreign Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	297	274
Level II [Member] | States, Municipalities And Political Subdivisions [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	3,772	4,143
Level II [Member] | Corporate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	13,222	12,392
Level II [Member] | Residential Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	3,315	2,663
Level II [Member] | Commercial Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	2,082	1,878
Level II [Member] | Other Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	3,665	3,382
Level II [Member] | Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	19	41
Level II [Member] | Equity Securities [Member] | Exchange Traded Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	0	0
Level II [Member] | Equity Securities [Member] | Common Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	19	41
Level II [Member] | Equity Securities [Member] | Private Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	0	0
Level II [Member] | Other Investments [Member] | Common Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	0	0
Level II [Member] | Derivatives [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	3	3
Derivative liabilities	(69)	(60)
Level III [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Available-for-sale Securities	469	493
Securities lending collateral	0	0
Total assets	544	581
Total liabilities	0	0
Level III [Member] | United States Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level III [Member] | Government Sponsored Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level III [Member] | Foreign Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level III [Member] | States, Municipalities And Political Subdivisions [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level III [Member] | Corporate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	103	137
Level III [Member] | Residential Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level III [Member] | Commercial Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level III [Member] | Other Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	366	356
Level III [Member] | Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	75	88
Level III [Member] | Equity Securities [Member] | Exchange Traded Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	0	0
Level III [Member] | Equity Securities [Member] | Common Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	0	0
Level III [Member] | Equity Securities [Member] | Private Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	75	88
Level III [Member] | Other Investments [Member] | Common Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	0	0
Level III [Member] | Derivatives [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	0	0
Derivative liabilities	$ 0	$ 0

Fair Value (Reconciliation Of T

Fair Value (Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 610	$ 481	$ 581	$ 449
Total gains (losses) recognized in net income	1	(7)	(7)	(3)
Total gains (losses) recognized in accumulated other comprehensive loss	(8)		(2)	(2)
Purchases	9	212	23	260
Sales	(20)	(202)	(30)	(191)
Settlements	(4)	(5)	(6)	(39)
Transfers into Level III	6	14	6	14
Transfers out of Level III	(50)	(26)	(21)	(21)
Ending balance	544	467	544	467
Change in unrealized gains (losses) included in net income related to assets still held	1	(3)	(6)	1
Corporate Securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	142	341	137	336
Total gains (losses) recognized in net income	(2)	(5)	(3)	(4)
Total gains (losses) recognized in accumulated other comprehensive loss	1		2	(2)
Purchases	2	11	4	35
Sales	(10)	(188)	(10)	(175)
Settlements	(4)	(5)	(6)	(39)
Transfers into Level III	0	14	0	14
Transfers out of Level III	(26)	(13)	(21)	(10)
Ending balance	103	155	103	155
Change in unrealized gains (losses) included in net income related to assets still held	0	0	0	0
Residential Mortgage-Backed Securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	0	4	0	5
Total gains (losses) recognized in net income	0	0	0	0
Total gains (losses) recognized in accumulated other comprehensive loss	0		0	0
Purchases	0	0	0	0
Sales	0	0	0	0
Settlements	0	0	0	0
Transfers into Level III	0	0	0	0
Transfers out of Level III	0	(4)	0	(5)
Ending balance	0	0	0	0
Change in unrealized gains (losses) included in net income related to assets still held	0	0	0	0
Other Asset-backed Securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	390	37	356	19
Total gains (losses) recognized in net income	1	0	1	0
Total gains (losses) recognized in accumulated other comprehensive loss	(9)		(4)	0
Purchases	7	190	18	205
Sales	(5)	0	(11)	0
Settlements	0	0	0	0
Transfers into Level III	6	0	6	0
Transfers out of Level III	(24)	(9)	0	(6)
Ending balance	366	218	366	218
Change in unrealized gains (losses) included in net income related to assets still held	0	0	0	0
Equity Securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	78	99	88	89
Total gains (losses) recognized in net income	2	(2)	(5)	1
Total gains (losses) recognized in accumulated other comprehensive loss	0		0	0
Purchases	0	11	1	20
Sales	(5)	(14)	(9)	(16)
Settlements	0	0	0	0
Transfers into Level III	0	0	0	0
Transfers out of Level III	0	0	0	0
Ending balance	75	94	75	94
Change in unrealized gains (losses) included in net income related to assets still held	$ 1	$ (3)	$ (6)	$ 1

Fair Value (Carrying And Estima

Fair Value (Carrying And Estimated Fair Values by Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet) (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	$ 5,993	$ 5,685
Short-term borrowings	265	265
Notes	22,872	21,861
Convertible debentures		463
Fair Value, Recurring [Member] | Level III [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term borrowings	0	0
Notes	0	0
Convertible debentures		0
Fair Value, Recurring [Member] | Level II [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term borrowings	265	265
Notes	22,872	21,861
Convertible debentures		463
Fair Value, Recurring [Member] | Level I [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term borrowings	0	0
Notes	0	0
Convertible debentures		0
Fair Value, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	5,872	5,582
Short-term borrowings	265	265
Notes	24,859	23,786
Convertible debentures		63
Other Investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	5,872	5,582
Other Investments [Member] | Fair Value, Recurring [Member] | Level III [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	5,872	5,582
Other Investments [Member] | Fair Value, Recurring [Member] | Level II [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	0	0
Other Investments [Member] | Fair Value, Recurring [Member] | Level I [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	$ 0	$ 0

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income tax expense	$ 585	$ 488	$ 1,200	$ 1,015
Effective tax rate	24%	23%	23.70%	22.90%
Income taxes receivable	$ 48		$ 48		$ 440

Medical Claims Payable (Reconci

Medical Claims Payable (Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable) (Details) - USD ($) $ in Millions	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Medical Claims Payable [Line Items]
Gross medical claims payable, beginning of period		$ 15,348		$ 13,282	$ 15,348	$ 13,282
Ceded medical claims payable, beginning of period		(6)		(21)	(6)	(21)
Net medical claims payable, beginning of period		15,342		13,261	15,342	13,261
Business combinations and purchase adjustments					0	133
Current period net incurred medical claims					61,290	55,737
Prior periods redundancies					(1,112)	(972)
Total net incurred medical claims	$ 30,495	$ 29,683	$ 27,634	$ 27,131	60,178	54,765
Net payments attributable to current period medical claims					48,217	42,882
Net payments attributable to prior periods medical claims					11,409	10,401
Total net payments					59,626	53,283
Net medical claims payable, end of period	15,894		14,876		15,894	14,876
Ceded medical claims payable, end of period	8		13		8	13
Gross medical claims payable, end of period	$ 15,902		$ 14,889		$ 15,902	$ 14,889

Medical Claims Payable (Recon_2

Medical Claims Payable (Reconciliation Of Net Incurred Medical Claims To Benefit Expense) (Details) - USD ($) $ in Millions	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Reconciliation of net incurred medical claims to benefit expense [Line Items]
Total net incurred medical claims	$ 30,495	$ 29,683	$ 27,634	$ 27,131	$ 60,178	$ 54,765
Quality improvement and other claims expense	1,109	1,103	1,161	1,100	2,212	2,261
Benefit expense	$ 31,604	$ 30,786	$ 28,795	$ 28,231	$ 62,390	$ 57,026

Medical Claims Payable Medical

Medical Claims Payable Medical Claims Payable (Reconciliation of the Claims Development to the Claims Liability) (Details) - USD ($) $ in Millions	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]
Net medical claims payable, end of period	$ 15,894				$ 15,894		$ 15,342
Ceded medical claims payable end of period	8		$ 13		8	$ 13	6	$ 21
Insurance lines other than short duration	263				263		248
Gross medical claims payable, end of period	16,165				16,165		$ 15,596
Total net incurred medical claims	30,495	$ 29,683	27,634	$ 27,131	60,178	54,765
Quality improvement and other claims expense	1,109	1,103	1,161	1,100	2,212	2,261
Benefit expense	$ 31,604	$ 30,786	$ 28,795	$ 28,231	$ 62,390	$ 57,026

Medical Claims Payable (Narrati

Medical Claims Payable (Narrative) (Details) $ in Millions	Jun. 30, 2023 USD ($)
Short-Duration Insurance Contract, Accident Year 2021 [Member]
Claims Development [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 597
Short-Duration Insurance Contract, Accident Year 2022 [Member]
Claims Development [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	2,224
Short-Duration Insurance Contract, Accident Year 2023 [Member]
Claims Development [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 13,073

Debt (Narrative) (Details)

Debt (Narrative) (Details) - USD ($) $ in Millions		3 Months Ended	6 Months Ended
	Mar. 15, 2023	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022	Feb. 08, 2023	Jan. 17, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Repayments of Long-term Debt			$ 1,908	$ 943
Short-term borrowings		$ 265	$ 265				$ 265
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Covenant description			Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility.
Covenant compliance			As of June 30, 2023, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.6%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of June 30, 2023, we were in compliance with all of our debt covenants under the 5-Year Facility.
Maximum borrowing capacity		4,000	$ 4,000
Subsidiary Credit Facilities [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity		200	200
Federal Home Loan Bank Advances [Member]
Debt Instrument [Line Items]
Federal Home Loan Bank, advances, short-term		175	175				265
Surplus Notes [Member]
Debt Instrument [Line Items]
Long-term Debt		25	25				25
Senior Unsecured Notes [Member]
Debt Instrument [Line Items]
Long-term Debt		24,834	24,834				23,761
Senior Unsecured Notes [Member] | Four Point Nine Zero Zero Percent Due Two Thousand Twenty Six
Debt Instrument [Line Items]
Debt instrument interest rate					4.90%
Debt Instrument, Face Amount					$ 500
Senior Unsecured Notes [Member] | Four Point Seven Five Zero Percent Due Two Thousand Thirty Three
Debt Instrument [Line Items]
Debt instrument interest rate					4.75%
Debt Instrument, Face Amount					$ 1,000
Senior Unsecured Notes [Member] | Five Point One Two Five Percent Due Two Thousand Fifty Three
Debt Instrument [Line Items]
Debt instrument interest rate					5.125%
Debt Instrument, Face Amount					$ 1,100
Senior Unsecured Notes [Member] | Three Point Three Zero Zero Percent Due Two Thousand Twenty Three
Debt Instrument [Line Items]
Debt instruments, repurchased face amount						$ 1,000
Debt instrument interest rate						3.30%
Senior Unsecured Notes [Member] | Zero Point Four Five Zero Percent Due Two Thousand Twenty Three
Debt Instrument [Line Items]
Debt instruments, repurchased face amount	$ 500
Debt instrument interest rate	0.45%
Commercial Paper
Debt Instrument [Line Items]
Commercial paper authorized		4,000	4,000
Commercial paper		90	$ 90				$ 0
Senior Convertible Debenture [Member] | Two Point Seven Five Zero Percent Due Two Thousand Forty Two
Debt Instrument [Line Items]
Debt Conversion Debt Principal Amount		59
Repayments of Long-term Debt	$ 5	$ 404
Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed	100%

Commitments And Contingencies (

Commitments And Contingencies (Details) $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($)
Commitments And Contingencies [Line Items]
Gross premium tax rate, state of California	2.35%
Long-term purchase commitment, amount	$ 621
Minimum [Member]
Commitments And Contingencies [Line Items]
Aggregate settlement amount	0
Maximum [Member]
Commitments And Contingencies [Line Items]
Aggregate settlement amount	250
Anthem, Inc. v. Express Scripts, Inc. [Member]
Commitments And Contingencies [Line Items]
Proceeds originally received at time of divestiture	4,675
Anthem, Inc. v. Express Scripts, Inc. [Member] | Damages for Pharmacy Pricing [Member]
Commitments And Contingencies [Line Items]
Approximate amount of damages sought for breaches	14,800
Anthem, Inc. v. Express Scripts, Inc. [Member] | Damages for Operational Breaches [Member]
Commitments And Contingencies [Line Items]
Approximate amount of damages sought for breaches	158
BCBS Antitrust Litigation [Member]
Commitments And Contingencies [Line Items]
Aggregate settlement amount	596
Loss Contingency Accrual, Payments	$ 506

Capital Stock (Summary of Cash

Capital Stock (Summary of Cash Dividend Activity) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Banking Regulation, Total Capital [Abstract]
Declaration date	Apr. 18, 2023	Jan. 24, 2023	Apr. 19, 2022	Jan. 25, 2022
Record date	Jun. 09, 2023	Mar. 10, 2023	Jun. 10, 2022	Mar. 10, 2022
Payment date	Jun. 23, 2023	Mar. 24, 2023	Jun. 24, 2022	Mar. 25, 2022
Cash dividends per share	$ 1.48	$ 1.48	$ 1.28	$ 1.28
Total payment	$ 350	$ 351	$ 309	$ 309	$ 701	$ 618

Capital Stock (Summary of Share

Capital Stock (Summary of Share Repurchases) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Equity, Class of Treasury Stock [Line Items]
Shares repurchased				2.7	2.5
Average price per share				$ 466.62	$ 471.72
Aggregate cost	$ 652	$ 624	$ 545	$ 1,268	$ 1,169
Authorization remaining at the end of the period	$ 5,608	$ 3,022		$ 5,608	$ 3,022

Capital Stock (Summary of Stock

Capital Stock (Summary of Stock Option Activity) (Details) $ / shares in Units, shares in Millions, $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares
Number of Shares [Roll Forward]
Outstanding at beginning of period, Number of Shares | shares	2.8
Granted, Number of Shares | shares	0.6
Exercised, Number of Shares | shares	(0.2)
Forfeited or expired, Number of Shares | shares	0
Outstanding at end of period, Number of Shares | shares	3.2
Exercisable at end of period, Number of Shares | shares	2.1
Weighted-Average Option Price Per Share [Roll Forward]
Outstanding at beginning of period, Weighted-Average Option Price per Share | $ / shares	$ 293.28
Granted, Weighted-Average Option Price per Share | $ / shares	469.05
Exercised, Weighted-Average Option Price per Share | $ / shares	268.35
Forfeited or expired, Weighted-Average Option Price per Share | $ / shares	391.44
Outstanding at end of period, Weighted-Average Option Price per Share | $ / shares	323.85
Exercisable at end of period, Weighted-Average Option Price per Share | $ / shares	$ 265.51
Outstanding at end of period, Weighted-Average Remaining Contractual Life	6 years 6 months 3 days
Exercisable at end of period, Weighted-Average Remaining Contractual Life	5 years 3 months 21 days
Outstanding at end of period, Aggregate Intrinsic Value | $	$ 402
Exercisable at end of period, Aggregate Intrinsic Value | $	$ 376

Capital Stock (Nonvested Restri

Capital Stock (Nonvested Restricted Stock Activity Including Restricted Stock Units) (Details) - $ / shares shares in Millions	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Restricted Stock Shares and Units [Roll Forward]
Nonvested at Beginning Balance, Restricted Stock Shares and Units	1.2
Granted, Restricted Stock Shares and Units	0.6
Vested, Restricted Stock Shares And Units	(0.6)
Forfeited, Restricted Stock Shares And Units	0
Nonvested at Ending Balance, Restricted Stock Shares and Units	1.2
Weighted-Average Grant Date Fair Value Per Share [Roll Forward]
Nonvested at Beginning Balance, Weighted-Average Grant Date Fair Value per Share	$ 357.21
Granted, Weighted-Average Grant Date Fair Value per Share	469.60	$ 452.78
Vested, Weighted-Average Grant Date Fair Value per Share	301.18
Forfeited, Weighted-Average Grant Date Fair Value per Share	405.25
Nonvested at Ending Balance, Weighted-Average Grant Date Fair Value per Share	$ 422.67

Capital Stock (Fair Values of O

Capital Stock (Fair Values of Options Granted During The Period Estimated Using Weighted-Average Assumptions) (Details)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Banking Regulation, Total Capital [Abstract]
Risk-free interest rate	3.95%	1.97%
Volatility factor	29%	29%
Quarterly dividend yield	0.316%	0.282%
Weighted-average expected life (years)	4 years 4 months 24 days	5 years 1 month 6 days

Capital Stock (Schedule Of Weig

Capital Stock (Schedule Of Weighted-Average Fair Values Determined For The Periods) (Details) - $ / shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Banking Regulation, Total Capital [Abstract]
Options granted during the period	$ 127.13	$ 116.80
Restricted stock awards granted during the period	$ 469.60	$ 452.78

Capital Stock (Narrative) (Deta

Capital Stock (Narrative) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions		3 Months Ended				6 Months Ended
	Jul. 18, 2023	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jan. 26, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Dividends Payable, Date to be Paid		Jun. 23, 2023	Mar. 24, 2023	Jun. 24, 2022	Mar. 25, 2022
Dividends Payable, Date of Record		Jun. 09, 2023	Mar. 10, 2023	Jun. 10, 2022	Mar. 10, 2022
Increase In Stock Repurchase Program Authorization							$ 5,000
Subsequent Event [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Dividends Payable, Amount Per Share	$ 1.48
Dividends Payable, Date to be Paid	Sep. 22, 2023
Dividends Payable, Date of Record	Sep. 08, 2023
2023 to 2025 | Restricted Stock Units (RSUs) [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						0.2

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss (Reconciliation Of The Components Of Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Millions	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Accumulated Other Comprehensive Loss, Beginning Balance	$ (2,050)	$ (2,490)	$ (1,246)	$ (197)	$ (2,490)	$ (197)
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax	(119)		(922)		308	(1,991)
Other comprehensive loss (income) attributable to noncontrolling interests	0		3		(2)	8
Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest	0		(1)		0	(3)
Cash flow hedges, holding gain (loss), net of tax	4		3		15	6
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax	3		9		5	16
Change in future policy benefits, net of tax	(3)		8		(1)	17
Foreign currency translation adjustment, net of tax	0		(5)		2	(8)
Other Comprehensive Income (Loss), Net of Tax	(116)	442	(908)	(1,054)	326	(1,962)
Accumulated Other Comprehensive Loss, Ending Balance	(2,166)	(2,050)	(2,151)	(1,246)	(2,166)	(2,151)
Other Comprehensive Income (Loss), Tax (Expense) Benefit, Portion Attributable to Parent	32		285		(72)	617
Net unrealized investment (losses) gains
AOCI, Debt Securities, Beginning Balance	(1,330)	(1,755)	(570)	494	(1,755)	494
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax	(191)		(1,050)		146	(2,196)
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax	72		128		162	205
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax	(119)		(922)		308	(1,991)
Other comprehensive loss (income) attributable to noncontrolling interests	0		3		(2)	8
AOCI, Debt Securities, Ending Balance	(1,449)	(1,330)	(1,489)	(570)	(1,449)	(1,489)
Net holding gain (loss) on investment securities arising during the period, tax (expense) benefit	61		323		(25)	677
Reclassification adjustment for net realized loss (gain) on investment securities, tax (benefit) expense	(23)		(34)		(51)	(55)
Non-credit components of impairments on investments [Member]
AOCI, Other than Temporary Impairment, Not Credit Loss, Beginning Balance	(5)	(3)	(1)	0	(3)	0
Other than Temporary Impairment Losses, Investments, Portion in Other Comprehensive Loss, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Available-for-sale Securities	(1)		(1)		(3)	(2)
AOCI, Other than Temporary Impairment, Not Credit Loss, Ending Balance	(6)	(5)	(2)	(1)	(6)	(2)
Tax (expense) benefit of non credit impairment on available-for-sale securities recognized in other comprehensive income (loss)	0		0		1	1
Net cash flow hedges
AOCI, Cash Flow Hedge, Beginning Balance	(218)	(229)	(236)	(239)	(229)	(239)
Cash flow hedges, holding gain (loss), net of tax	4		3		15	6
AOCI, Cash Flow Hedge, Ending Balance	(214)	(218)	(233)	(236)	(214)	(233)
Cash flow hedges, holding gain (loss), tax (expense) benefit	(1)		(1)		7	(2)
Pension and other postretirement benefits
AOCI, Defined Benefit Plan, Beginning Balance	(497)	(499)	(422)	(429)	(499)	(429)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax	3		9		5	16
AOCI, Defined Benefit Plan, Ending Balance	(494)	(497)	(413)	(422)	(494)	(413)
Net change in unrecognized periodic benefit costs for defined benefit pension and postretirement benefit plans, tax expense	(1)		(4)		(2)	(6)
Future Policy Benefits
AOCI, Liability for Future Policy Benefit, After Tax, Beginning Balance	15	13	(10)	(19)	13	(19)
Change in future policy benefits, net of tax	(3)		8		(1)	17
AOCI, Liability for Future Policy Benefit, After Tax, Ending Balance	12	15	(2)	(10)	12	(2)
Change in future policy benefits, tax expense	1		0		1	0
Foreign currency translation adjustments
AOCI, Foreign Currency Translation Adjustment, Net of Tax, Beginning Balance	(15)	(17)	(7)	(4)	(17)	(4)
Foreign currency translation adjustment, net of tax	0		(5)		2	(8)
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax, Ending Balance	(15)	$ (15)	(12)	$ (7)	(15)	(12)
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax (Expense) Benefit	$ (5)		$ 1		$ (3)	$ 2

Earnings Per Share (Denominator

Earnings Per Share (Denominator For Basic And Diluted Earnings Per Share) (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share [Abstract]
Denominator for basic earnings per share - weighted-average shares	236.6	240.7	237	241
Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures	1.2	2.7	1.7	2.9
Denominator for diluted earnings per share	237.8	243.4	238.7	243.9

Earnings Per Share (Narrative)

Earnings Per Share (Narrative) (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share [Abstract]
Weighted average shares excluded from denominator for diluted earnings per share because the stock options were anti-dilutive	1	0.5	0.7	0.4
Restricted stock units issued under stock incentive plan			0.6
2022 to 2024 [Member]
Restricted stock units issued under stock incentive plan		0		0.5
Restricted stock units excluded from the denominator for diluted earnings per share		0		0.2
2023 to 2025
Restricted stock units issued under stock incentive plan	0		0.6
Restricted stock units excluded from the denominator for diluted earnings per share	0		0.2

Segment Information (Financial

Segment Information (Financial Data By Reportable Segment) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting Information [Line Items]
Premiums	$ 36,589	$ 33,076	$ 72,457	$ 65,861
Product revenue	4,859	3,568	8,881	6,869
Service fees	1,929	1,838	3,937	3,638
Total operating revenue	43,377	38,482	85,275	76,368
Operating gain (loss)	2,628	2,346	5,459	4,773
Health Benefits Segment
Segment Reporting Information [Line Items]
Premiums	36,233	32,787	71,767	65,250
Product revenue	0	0	0	0
Service fees	1,767	1,609	3,513	3,173
Total operating revenue	38,000	34,396	75,280	68,423
Operating gain (loss)	2,148	1,781	4,307	3,632
Carelon Total
Segment Reporting Information [Line Items]
Premiums	429	327	839	693
Product revenue	4,859	3,568	8,881	6,869
Service fees	201	220	408	446
Total operating revenue	11,907	10,054	23,243	19,685
Operating gain (loss)	632	592	1,353	1,190
Carelon Services Segment
Segment Reporting Information [Line Items]
Premiums	429	327	839	693
Product revenue	0	0	0	0
Service fees	201	220	408	446
Total operating revenue	3,441	2,983	6,753	5,931
Operating gain (loss)	136	113	345	313
CarelonRx Segment [Member]
Segment Reporting Information [Line Items]
Premiums	0	0	0	0
Product revenue	4,859	3,568	8,881	6,869
Service fees	0	0	0	0
Total operating revenue	8,466	7,071	16,490	13,754
Operating gain (loss)	496	479	1,008	877
Corporate & Other Segment
Segment Reporting Information [Line Items]
Premiums	0	0	0	0
Product revenue	0	0	0	0
Service fees	(39)	9	16	19
Total operating revenue	287	315	538	588
Operating gain (loss)	(152)	(27)	(201)	(49)
Segment Eliminations [Member]
Segment Reporting Information [Line Items]
Premiums	(73)	(38)	(149)	(82)
Total operating revenue	(6,817)	(6,283)	(13,786)	(12,328)
Operating gain (loss)	0	0	0	0
Unaffiliated
Segment Reporting Information [Line Items]
Total operating revenue	43,377	38,482	85,275	76,368
Unaffiliated | Health Benefits Segment
Segment Reporting Information [Line Items]
Total operating revenue	38,000	34,396	75,280	68,423
Unaffiliated | Carelon Total
Segment Reporting Information [Line Items]
Total operating revenue	5,489	4,115	10,128	8,008
Unaffiliated | Carelon Services Segment
Segment Reporting Information [Line Items]
Total operating revenue	630	547	1,247	1,139
Unaffiliated | CarelonRx Segment [Member]
Segment Reporting Information [Line Items]
Total operating revenue	4,859	3,568	8,881	6,869
Unaffiliated | Corporate & Other Segment
Segment Reporting Information [Line Items]
Total operating revenue	(39)	9	16	19
Unaffiliated | Segment Eliminations [Member]
Segment Reporting Information [Line Items]
Total operating revenue	(73)	(38)	(149)	(82)
Affiliated [Member] | Carelon Total
Segment Reporting Information [Line Items]
Total operating revenue	6,418	5,939	13,115	11,677
Affiliated [Member] | Carelon Services Segment
Segment Reporting Information [Line Items]
Total operating revenue	2,811	2,436	5,506	4,792
Affiliated [Member] | CarelonRx Segment [Member]
Segment Reporting Information [Line Items]
Total operating revenue	3,607	3,503	7,609	6,885
Affiliated [Member] | Corporate & Other Segment
Segment Reporting Information [Line Items]
Total operating revenue	326	306	522	569
Affiliated [Member] | Segment Eliminations [Member]
Segment Reporting Information [Line Items]
Total operating revenue	$ (6,744)	$ (6,245)	$ (13,637)	$ (12,246)

Segment Information (Reconcilia

Segment Information (Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting [Abstract]
Total operating revenue	$ 43,377	$ 38,482	$ 85,275	$ 76,368
Net investment income	416	381	803	741
Net losses on financial instruments	(121)	(231)	(234)	(382)
Total revenues	$ 43,672	$ 38,632	$ 85,844	$ 76,727

Segment Information (Reconcil_2

Segment Information (Reconciliation Of Income Before Income Tax Expense To Reportable Segments Operating Gain Included In The Consolidated Statements Of Income) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting [Abstract]
Income before income tax expense	$ 2,441	$ 2,122	$ 5,060	$ 4,428
Net investment income	(416)	(381)	(803)	(741)
Net losses (gains) on financial instruments	121	231	234	382
Interest expense	261	208	512	409
Amortization of other intangible assets	221	166	456	295
Reportable segments operating gain	$ 2,628	$ 2,346	$ 5,459	$ 4,773

Segment Information Segment Inf

Segment Information Segment Information (Narrative) (Details)	6 Months Ended
	Jun. 30, 2023 segment
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of Reportable Segments	4

Leases (Lease and Other Informa

Leases (Lease and Other Information) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Assets and Liabilities, Lessee
Operating Lease, Right-of-Use Asset	$ 605		$ 605		$ 604
Operating Lease, Liability, Current	178		178		181
Operating Lease, Liability, Noncurrent	$ 717		$ 717		$ 751
Balance sheet location of operating lease right-of-use assets	Other noncurrent assets		Other noncurrent assets		Other noncurrent assets
Balance sheet location of current operating lease liabilities	Other current liabilities		Other current liabilities		Other current liabilities
Balance sheet location of noncurrent operating lease liabilities	Other noncurrent liabilities		Other noncurrent liabilities		Other noncurrent liabilities
Lease, Cost and Other Information [Abstract]
Operating Lease, Cost	$ 32	$ 33	$ 57	$ 65
Short-term Lease, Cost	16	11	29	24
Sublease Income	(1)	(1)	(2)	(2)
Lease, Cost	47	43	84	87
Operating Lease, Payments	54	53	105	105
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 18	$ 29	$ 40	$ 37

Leases (Reconciliation of Futur

Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) (Details) $ in Millions	Jun. 30, 2023 USD ($)
Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
Operating lease payments, 2023; excluding the six months ended June 30, 2023	$ 110
Operating lease payments, 2024	195
Operating lease payments, 2025	162
Operating lease payments, 2026	128
Operating lease payments, 2027	93
Operating lease payments, Thereafter	329
Total future minimum payments	1,017
Imputed Interest, Leases	122
Operating Lease Liabilities	$ 895

Leases (Narrative) (Details)

Leases (Narrative) (Details)	Jun. 30, 2023	Dec. 31, 2022
Lessee, Lease and Other Information [Line Items]
Operating Lease, Weighted Average Remaining Lease Term	7 years	7 years
Weighted Average Discount Rate, Percent	3.28%	2.98%
Minimum [Member]
Lessee, Lease and Other Information [Line Items]
Lessee, Operating Lease, Term of Contract	1 year
Maximum [Member]
Lessee, Lease and Other Information [Line Items]
Lessee, Operating Lease, Term of Contract	11 years